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Chapter 1 
 
INTRODUCTION 
 
Schizophrenia is a complex multifactorial chronic and disabling mental disorder affecting one of hundred 
people worldwide. It is a syndrome of signs and symptoms of unknown etiology, predominantly defined 
by signs of psychosis (Insel 2010). Psychosis is commonly considered as a rare phenomenon outside the 
range of normal experience giving rise to significant disability (Dominguez, et al. 2011). 
The history of this mental illness goes back thousands of years from the mental symptoms resembling 
schizophrenia as signs of heart diseases in the ancient Egypt and the evil possession of the body in middle 
ages. Its modern history dates to Emil Kraepelin who defined schizophrenia as premature dementia in 
young adults in the late nineteenth century (Kraepelin 1919). At the beginning of the twentieth century, 
Eugen Bleuler introduced the term ‘schizophrenia’ and described four ‘A’ disturbances: associations, 
affect, ambivalence, and autistic isolation (Bleuler 1920). Kurt Schneider emphasized psychotic 
symptoms as delusions and hallucinations and narrowed the definition of schizophrenia (Schneider 1959). 
The DSM-IV (Diagnosis and Statistical Manual of Mental Disorder-IV) definition synthesizes 
abovementioned signs: a Kraepelinian emphasis on course, Schneiderian positive psychotic symptoms 
and Bleuler’s reconceptualized negative symptoms (Andreasen and Black 2001). Nowadays the 
characterization as a neurodevelopmental disease is accepted (Pantelis, et al. 2003b). It is postulated, that 
a set of basic biological abnormalities that occur early in life leads to a combination of structural, 
functional, and/or biochemical anomalies in the developing brain (Cannon, et al. 1993). Currently two 
neuronal disruption pathways are assumed: pruning-related plasticity process during adolescence 
(Bartzokis, et al. 2003) and stress-related neurotoxic effects (Hof, et al. 2003). 
Psychosis nearly always emerges in late adolescence or early adulthood. It means in a period of life 
characterized already in healthy typically developing individuals by rapid changes in biological, 
cognitive, and emotional development. Global gray matter starts to decrease gradually and global white 
matter continues to increase in healthy subjects (Sowell, et al. 1999). This process seems to be impaired 
in people prone to psychosis. 
Characteristic features of psychosis are impaired insight into the pathological nature of experienced 
delusions or hallucinations (Lysaker, et al. 2007; Mohamed, et al. 2009; Palaniyappan, et al. 2010), as 
well as cognitive and functional alterations. Along with the ‘positive’ symptoms such as hallucinations, 
ego-disturbances and delusions, the typical loss of functioning accompanied with lack of energy and 
social withdrawal belong to the ‘negative’ symptoms.  
The underlying pathophysiology of schizophrenia is not entirely understood (Thompson, et al. 2009) but 
involves dysregulation in several neurotransmitter systems in the brain. A previously postulated 
hyperdopaminergic hypothesis based on the antagonistic effect of antipsychotics on D2-receptors has 
been changed. There is neither single abundance nor single deficiency of dopamine in the psychotic 
brains (Carlsson 1988). Along with this dopamine dysregulation, serotonin, Gamma aminobutyric acid 
 
 
2 
(GABA) and glutamate (Carlsson 2006) may induce both the positive and the negative symptoms of 
schizophrenia and contribute to cognitive deficits and functional decline.  
 
1.1 Pharmacological treatment of psychosis 
 
Despite decades of research and advances in interventions, schizophrenia continues to be one of the most 
severe psychiatric disorders. The pharmacological intervention has been changing parallel to the growing 
understanding of neurobiological basis of schizophrenia. During the 1950’s and 1960’s, the typical 
antipsychotics revolutionized its treatment. The typical antipsychotics (such as chlorpromazine, 
haloperidol, loxapine, molindone, perphenazine, sulpiride and thioridazine) were primarily referred as 
first generation or conventional antipsychotics. Their antagonistic mode of action on the D2-receptors 
(Carlsson 1978; Seeman, et al. 1975) leads mainly to the reduction of positive symptoms. The typical 
antipsychotics have no effect on negative and cognitive symptoms and could cause side effects such as 
extra-pyramidal symptoms, sedation, and prolactin elevation (Stahl 2008).   
Atypical antipsychotics – also known as second generation antipsychotics - (for example olanzapine, 
risperidone, quetiapine, clozapine, ziprasidone and aripiprazole) showed highly specific pharmacological 
properties depending on their unique receptor profiles. Although the atypical antipsychotics offered better 
tolerability (substantially lower risk of extrapyramidal symptoms), there were still cardio-metabolic side 
effects and weight gain occurring (Lieberman, et al. 2008) and no significantly better effect on functional 
recovery and cognitive deficits compared to typical antipsychotics (Keefe, et al. 2007). Recent animal and 
human studies have shown that both typical and atypical antipsychotic agents may cause alterations of 
regional gray matter volumes (Dazzan, et al. 2005; Konopaske, et al. 2008; Navari and Dazzan 2009) that 
were not solely attributable to disease-related effects. 
 
1.2 The prodromal stage of schizophrenia  
 
The prodromal stages of serious physical diseases, e.g. cardiovascular and oncological diseases, have 
become more attention recently. Similarly, over the last decades early clinical detection and intervention 
in patients with psychoses has become widespread.  Psychosis seems to be preventable or at least 
successfully treatable in the early stages (McGorry, et al. 2007). Early detection services worldwide 
(Mechelli, et al. 2010; Riecher-Rössler, et al. 2009; Yung, et al. 1998) identify individuals, who are 
experiencing prodromal symptoms characterized by attenuated psychotic symptoms and a decline in 
social and occupational function and broadly termed as having a clinical high-risk or at risk mental state 
(for review see (Riecher-Rössler, et al. 2006)). Research in early and prodromal phases of the illness may 
provide important etiology findings that are not confounded by medication and/or chronic disease related 
effects. 
The developing psychosis is understood as a continuum with early mild clinical signs. A high-risk state of 
psychosis may be a consequence of a genetic predisposition (Lawrie, et al. 2008) and/or gene-
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neurodevelopmental interaction (Borgwardt, et al. 2007b; DeLisi 2008; Pantelis, et al. 2005) and/or other 
stress factors leading to the increased clinical risk for psychosis. Around 20-30% (Riecher-Rössler, et al. 
2007; Riecher-Rössler, et al. 2009; Yung, et al. 1998) of these high-risk individuals go on to develop 
psychosis with more severe symptoms and some of them continue to a serious chronic disease. Research 
has attempted to identify definitive markers that distinguish those, who go on to develop psychosis from 
those, who do not. However, it is difficult to identify the individuals, who will later develop psychosis on 
clinical or symptomatic grounds. Therefore, we are facing the need to characterize vulnerability- and 
resilience-associated neurobiological markers. Neuroimaging methods help to clarify the mechanisms 
underlying psychosis, as the same individuals can be studied before and after the onset of illness, often 
with only minimal confounding effects of the previous treatment. 
The term ‘at-risk mental state’ (ARMS) has been suggested as a replacement of the term ‘prodromal’, to 
delineate a subthreshold syndrome that confers high – but not inevitable – risk for development of 
psychotic disorder in the near future (Yung, et al. 1998). The ARMS is defined according to the PACE 
(Personal Assessment and Crisis Evaluation Clinic, Melbourne) criteria and requires individuals to 
present attenuated positive psychotic or brief limited intermittent symptoms that do not reach full 
psychosis threshold (Riecher-Rössler, et al. 2007; Riecher-Rössler, et al. 2009; Yung, et al. 2004) or 
functional decline. These psychopathological symptoms are often associated with negative symptoms 
(Lencz, et al. 2004; Riecher-Rössler, et al. 2009), subtle cognitive deficits (Brewer, et al. 2006; Riecher-
Rössler, et al. 2009) and include deficits in cognitive domains (Broome, et al. 2010; Simon, et al. 2007). 
Furthermore, neurofunctional deficits may be associated with transition to psychosis and thus can be seen 
as vulnerability markers for developing schizophrenia (Morey, et al. 2005; Riecher-Rössler, et al. 2009).  
 
1.3 Transition to psychosis and resilience factors 
 
Importantly, most of the ARMS individuals who made transition (90.5%) did so in the first two years 
after their ARMS was ascertained (ARMS with transition, ARMS-T). After these two years, only 3% of 
included ARMS individuals developed psychosis {Riecher-Rössler, 2009, Efficacy of using cognitive 
status in predicting psychosis: a 7-year follow-up}. In a study by Yung, the vast majority of transitions 
occurred in the first two years (estimated hazard ratio 0.58) and significantly dropped over time 
(estimated hazard ratio 0.07) (Yung, et al. 2007). 
Some recent studies aiming to improve individual risk assessment also report, that transition rate was 
declining over time (Haroun, et al. 2006; Ruhrmann, et al. 2010). During first two years, the transition 
rate declined from 31% published in 2003 (Pantelis, et al. 2003a) to 16% published five years later in the 
high-risk population (Yung, et al. 2008). This decline could be the result of non-pharmacological 
interventions, such as psychosocial intervention, family support, cognitive behavioral therapy (CBT) or 
other unknown (possibly protective) factors.   
Some ARMS individuals may have better internal resources, attitudinal approaches and overall 
functioning as seen by unmedicated schizophrenia patients (Harrow and Jobe 2007). They may recover 
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subsequently (Simon and Umbricht 2010). Other individuals may be on the ARMS continuum for a 
longer period of time. The more the subclinical psychosis persist in general population over time, the 
greater the risk of transition to clinical psychosis as showed an 8–year study (Dominguez, et al. 2011). 
Those ARMS individuals, who are more vulnerable to transition, can have less resilient factors and vice 
versa. That is the reason, why we suggest splitting the individuals in at-risk mental state according to the 
duration of their ARMS as well as according to their outcome (Figure 1). The first criterion focuses on 
the time aspect of risk: the short-term ARMS (ARMS-ST) group are ARMS individuals for a period of 
two years starting the first day of their ARMS; to the second group (long-term ARMS, ARMS-LT) 
belong individuals, who are in ARMS continuum longer than two years. ARMS-LT individuals represent 
a group with a vulnerability to psychosis but a reduced transition probability (Riecher-Rössler, et al. 
2009). It is essential, that all of the ARMS (ARMS-ST and ARMS-LT) still meet the PACE criteria and 
no individuals who recovered are included. ARMS-ST subjects are vulnerable to psychosis and 20-40% 
out of them will transit (ARMS-T) in next two years, leaving still 60-80% of ARMS without transition to 
psychosis - ARMS-NT (ARMS with no transition to psychosis). Actually those ARMS-NT, who did not 
recover and still fulfill ARMS criteria are of high importance and should be called ARMS-LT. We should 
follow them with the aim to investigate resilience factors protecting them in the process of on-going 
psychosis.  
Thus the two ARMS subgroups (ARMS-ST and ARMS-LT) represent vulnerability to psychosis with 
different probabilities of later transition to psychosis. ARMS-LT group is clearly on the risk continuum to 
develop psychosis, but according to the published data has lower probability to develop subsequent 
psychosis than ARMS-ST. This interesting group could help us to define resilient factors in at risk mental 
state. 
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Figure 1: ARMS population vulnerable to psychosis with descending transition probability in a time course of 
their at-risk state. 
 
ARMS individuals can be divided according to the duration of their at-risk mental state into ARMS-ST (ARMS 
short-term) and ARMS-LT (ARMS long-term) individuals. ARMS individuals with subsequent transition to 
psychosis (ARMS-T) can continue to develop first episode of psychosis (FE). ARMS-LT can be followed-up 
clinically and investigated for their vulnerability- and resilience-associated factors. 
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1.4 Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) techniques permits the examination of brain structure (sMRI) and 
function (fMRI) in vivo. MRI is a non-invasive method, safe scanning procedure without necessity to use 
ionizing radiation or injection of chemical substances. MRI scanner uses a strong magnetic field and radio 
transmitter and creates 2D or 3D image slices. Image resolution of sMRI images allows differentiating 
between gray (neurons and neuropil), white (myelinated fiber connections between neurons) matter tissue 
and cerebro-spinal fluid (CSF). By using the paramagnetic properties of oxygenated and deoxygenated 
hemoglobin and measuring the blood-oxygen-level-dependent (BOLD) contrast, regional cerebral blood 
flow and resulting ‘brain activity’ during cognitive task (McGuire, et al. 2008) can be compared across 
groups. 
 
1.4.1 Structural brain imaging findings in ARMS 
 
Over the past decade, sMRI methods have been extensively employed to identify the anatomical 
alterations in the pre-psychotic phases. Several techniques were implemented to investigate structural 
differences in ARMS individuals: voxel-based morphometry for gray matter (Borgwardt, et al. 2007a; 
Koutsouleris, et al. 2009; Pantelis, et al. 2003b) and white matter (Walterfang, et al. 2008), region-of-
interest approach (Fornito, et al. 2008; Phillips, et al. 2002; Takahashi, et al. 2009a; Thompson, et al. 
2007; Velakoulis, et al. 2006; Wood, et al. 2005; Yucel, et al. 2003), cortical pattern matching (Sun, et al. 
2009; Takahashi, et al. 2009b), and gyrification index (Harris, et al. 2007).  In subjects at high-risk for 
psychosis with subsequent transition to psychosis, as compared to the high-risk individuals without 
subsequent transition, MRI studies showed volumetric reductions in frontal, insular, cingulate, lateral and 
middle temporal, and cerebellar regions (Borgwardt, et al. 2007a; Borgwardt, et al. 2008; Borgwardt, et 
al. 2007b; Fornito, et al. 2008; Koutsouleris, et al. 2009; Pantelis, et al. 2003a; Pantelis, et al. 2003b; Sun, 
et al. 2009; Takahashi, et al. 2009a; Takahashi, et al. 2009b).  
These regions are compatible with the regions of structural deficits found in first-episode schizophrenia 
(Kasai, et al. 2003; Lieberman, et al. 2001; Steen, et al. 2006; Vita, et al. 2006; Witthaus, et al. 2008) and 
in the relatives of schizophrenic patients (Borgwardt, et al. 2010; Goghari, et al. 2007). The latter 
indicates that volumetric reductions in these regions represent potential vulnerability markers for 
psychosis. 
 
1.4.2 Neuropsychological findings in ARMS 
 
Executive function impairments including working memory (WM) (Callicott, et al. 2003a; Cannon, et al. 
2005; Forbes, et al. 2009; Glahn, et al. 2005; Jansma, et al. 2004; Johnson, et al. 2006; Manoach, et al. 
2000; Menon, et al. 2001; Schneider, et al. 2007), spatial memory and verbal fluency deficits (Becker, et 
al. 2010; Frommann, et al. 2010; Fusar-Poli, et al. 2010b; Hambrecht, et al. 2002; Korver, et al. 2010; 
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Ozgurdal, et al. 2009; Pauly, et al. 2010; Seidman, et al. 2010), and reward and salience processing 
anomalies (Juckel, et al. 2006; Murray, et al. 2008; Roiser, et al. 2009; Simon, et al. 2010) are 
pronounced cognitive features found in schizophrenia. However, the relation of physiological and clinical 
variables (positive, negative symptoms) is complicated by the multidimensional nature of psychotic 
symptoms. Recent advances in psychiatric research indicate that neurocognitive deficits are also evident 
in subjects with an at-risk mental state (ARMS) (Eastvold, et al. 2007; Marjoram, et al. 2006; Pflueger, et 
al. 2007; Simon, et al. 2007; Smith, et al. 2006) and in non-affected first-degree relatives (Karch, et al. 
2009; Karlsgodt, et al. 2007; Lee, et al. 2010a; MacDonald, et al. 2009; Meda, et al. 2008; Spence, et al. 
2000).  
 
1.4.3 Functional brain imaging findings in ARMS 
 
The fMRI studies are based on the known impaired cognitive domains in the early stages of 
schizophrenia. They use an ‘activation paradigm’, which engages the brain region/s of interest and the 
results reflect abnormalities under these specific cognitive domains.  Some of the published fMRI studies 
investigated neurofunctional abnormalities in ARMS and found deficits in the frontal and temporal task-
related networks (Allen, et al. 2010; Fusar-Poli, et al. 2007a). Several studies focused on functional 
deficits, while performing a working memory task (Broome, et al. 2010; Broome, et al. 2009; Fusar-Poli, 
et al. 2010c; Fusar-Poli, et al. 2010d). Such alterations cannot be attributed to the effects of illness or 
treatment and may represent markers of vulnerability to psychosis (Fusar-Poli, et al. 2007a).  
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Chapter 2 
  
GENERAL OUTLINE AND AIMS OF THE THESIS 
 
Post-mortem and neuroimaging studies of schizophrenic or psychotic patients showed less gray matter 
volumes and larger ventricles than brains of healthy people (Wright, et al. 2000). Although the majority 
of the included patients had history of antipsychotic treatment, the effect of antipsychotics on the brain 
structure received previously little attention. Apart from that, drug treatment might induce detectable 
changes in the brain of treated individuals (Dazzan, et al. 2005). This was the reason, why we firstly 
reviewed the effect of antipsychotics on the brain structure of schizophrenic patients treated with different 
antipsychotics. Our results are described and discussed in the chapter 4.1. We also contributed to the 
growing discussion in this clinically relevant issue with our two letters to the editors and with a 
commentary to recently published paper. 
Beside of the effect of antipsychotics there are also other possible confounders in studies with psychotic 
individuals, such as duration of their psychotic symptoms, comorbidity with other symptoms, medication 
with antidepressants and substance abuse. That is why the other aim of my thesis, addressed in the 
chapter 4.2, was to analyze the neuroimaging predictors of transition to psychosis. We focused on a 
population of high-risk individuals who are mostly not medicated yet and are at the beginning of their 
disease. In our meta-analysis we have evaluated the differences between those ARMS individuals who 
later developed psychosis and those, who did not. 
Initial theoretical analyses were followed by analyses of structural and functional neuroimaging data. We 
investigated individuals vulnerable to psychosis and those with the first episode of schizophrenia. 
Different probability for subsequent transition to psychosis was characterized according to the duration of 
the at risk mental state. We were interested in volumetric abnormalities in antipsychotic naïve high-risk 
individuals, as described in chapter 4.3. Additionally, we evaluated the association between volumetric 
abnormalities and clinical measures. 
Neurofunctional activation in a working memory task was evaluated together with gray matter volume as 
regressor in each voxel. This multimodal approach enables us to characterize the regions where functional 
abnormalities can be associated with volumetric deficits. Characterization of vulnerability- and psychosis-
related neurofunctional differences in a working memory network was the main aim of the study in 
chapter 4.4.  
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Chapter 3  
 
METHODS AND MATERIALS 
 
The detailed information about used methods and materials belongs to each manuscript of already 
published or submitted publication. These manuscripts are included in the respective paragraphs. All used 
methods are briefly described underneath. 
In the chapter 4.1, we performed a comprehensive electronic search on publications studying 
schizophrenia patients treated with antipsychotic medication. We presented a number of quantitate 
measures in informative tables and provided interpretation of the neuroimaging findings. We have 
focused on the antipsychotic medication, especially its type and doses, calculated chlorpromazine 
equivalents, and we characterized affected brain regions. 
Chapter 4.2 provides systematic review according to the ‘Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses’ (PRISMA) guidelines (Moher, et al. 2009). We have calculated the effect 
sizes with an estimator corrected for the number of subjects included in each study, using Cohen’s d 
statistic (Cohen 1992). Mean effect sizes were calculated for the most consistent results across the 
studies, i.e. for global brain volume measurements. 
Chapter 4.3 and 4.4 are based on specific population of individuals in the high risk to develop psychosis. 
Those were compared with first episode of psychosis patients and with matched healthy controls. 
Since 1999, the Early Detection of Psychosis Clinic (Früherkennung von Psychosen - FEPSY) in Basel 
recruited and followed up the ARMS individuals up to 7 years (Borgwardt, et al. 2007a; Riecher-Rössler, 
et al. 2007; Riecher-Rössler, et al. 2009). Subjects were assessed using the ‘Basel Screening Instrument 
for Psychosis’ (BSIP) (Riecher-Rössler, et al. 2008; Riecher-Rössler, et al. 2007), the Brief Psychiatric 
Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS) and the Global 
Assessment of Functioning (GAF). The BSIP evaluates ‘prodromal’ symptoms (defined according to the 
Diagnosis and Statistical Manual of Mental Disorder, DSM-III-R) occurring in the last 5 years; 
nonspecific ‘prodromal’ signs (Riecher-Rössler, et al. 2007) in the last 2 years; previous or current 
psychotic symptoms, psychosocial functioning over the last 5 years, substance dependency; and psychotic 
disorders among first and second degree relatives (Riecher-Rössler, et al. 2008).  
ARMS individuals were identified, examined, treated and followed-up at regular intervals: during the first 
year of follow-up once monthly, during the second and third year every 3 months, and thereafter annually 
(Riecher-Rössler, et al. 2009). Transition to psychosis was monitored according to the transition criteria 
(Yung, et al. 1998). We analyzed clinical and socio-demographic data using one-way analysis of variance 
(ANOVA) with the Statistical Package for Social Sciences (SPSS 16.0 and SPSS 19.0) 
In the chapter 4.3, we used T1-weighted MPRAGE sequences on a 3T scanner (Siemens Magnetom 
Verio, Siemens Healthcare, Erlangen, Germany) and examined the acquired images using SPM8 software 
(http://www.fil.ion.ucl.ac.uk/spm; Wellcome Department of Cognitive Neurology, London, United 
Kingdom). We preprocessed the images using voxel-based morphometry - VBM8 toolbox 
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(http://dbm.neuro.uni-jena.de/vbm8/) with integrated New Segmentation and DARTEL (Diffeomorphic 
Anatomical Registration Through Exponentiated Lie Algebra) approaches. Our segmented, normalized 
and smoothed images were entered into the statistical analysis of covariance (ANCOVA). The statistical 
model comprised age, gender, and total gray matter volume as covariates of no interest.  
Using the same scanner and echo planar (EPI) sequences we acquired fMRI images elicited with an n-
back (working memory) task (chapter 4.4). The reaction times and response accuracy were recorded on-
line. After exclusion of error trials, we convolved the onset times for each trial in seconds with a 
canonical hemodynamic response function. Firstly, we evaluated and described functional and structural 
data separately. The second important step was an integrative image analysis of two imaging data sets – 
fMRI data as the primary modality and structural VBM data as corresponding covariate. We used 
Biological Parametric Mapping (BPM) (Casanova, et al. 2007b) toolbox to provide this multimodal 
analyses with two imaging and three non-imaging covariates. 
Statistical inferences in our analyses were made at p<0.05 after family-wise error (FWE) correction and 
the regions of brain activation labeled in MNI coordinates were transformed into Talairach space 
(www.ebire.org/hcnlab/cortical-mapping; Talairach Daemon software). 
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ABSTRACT 
Background: Although individuals vulnerable to psychosis (ARMS) have brain volumetric 
abnormalities, structural alterations underlying different probabilities for later transition are unknown.  
Aim: We investigated gray matter volume (GMV) abnormalities by comparing two groups: long-term 
(ARMS-LT) and short-term (ARMS-ST) ARMS. 
Method: Using voxel-based morphometry (VBM), we examined 22 healthy controls (HC) together with 
18 ARMS-ST and 16 ARMS-LT, clinically followed for 3 months and 4.5 years on average, 
respectively.  
Results: The ARMS-ST had decreased bilateral insular and right middle temporal GMV compared to 
the ARMS-LT and this was positively correlated with functional decline. Compared to the HC, the 
ARMS-LT had higher right insular GMV. Insular and inferior-parietal alterations related to negative 
symptomatology in the ARMS.  
Conclusion: GMV abnormalities within the ARMS are related to different transition probabilities. 
Volume loss in the insula is associated with a higher risk for transition to psychosis.  
Declaration of interest: None. 
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INTRODUCTION 
There is a growing evidence of magnetic resonance imaging (MRI) that subjects at high clinical risk for 
psychosis have structural abnormalities in the frontal, insular and temporal regions. More recently MRI 
studies have examined whether there are specific neuroanatomical differences between high-risk subjects 
who subsequently develop psychosis and those who do not (for a review and meta-analysis of voxel-
based morphometry (VBM) studies in high risk subjects see (Fusar-Poli, et al. 2011; Smieskova, et al. 
2010)). Structural deficits associated with transition to psychosis can be seen as vulnerability markers for 
developing schizophrenia (Riecher-Rössler, et al. 2009; Smieskova, et al. 2010) and are of crucial 
relevance to the field of preventive interventions in psychosis.  
Early clinical intervention in psychosis has recently become a major objective of mental health services. 
Research at this stage is a potential way of investigating the mechanisms underlying psychosis, as the 
same individuals can be studied before and after the onset of illness, often with minimal confounding 
effects of previous antipsychotic treatment and illness duration. The identification of a clinical syndrome 
(an ‘At Risk Mental State’) that reflects an ‘ultra-high clinical risk’ predisposition to psychosis is 
fundamental to both clinical and research work in this area. Most transitions to psychosis in ARMS 
individuals were found in the first two years after baseline assessment and were much less probable later 
(Riecher-Rössler, et al. 2009; Yung, et al. 2007), suggesting rapid dynamic neurophysiological changes 
during the first two years of the pre-psychotic phases. Independent studies have confirmed complex 
neurophysiological changes underlying the prodromal psychotic phases involving not only brain structure 
but also cortical functioning and disrupted dopaminergic or glutamatergic neurotransmission (Hurlemann, 
et al. 2008; Jessen, et al. 2006). However, to our best knowledge no study has explicitly addressed 
potential neurobiological markers of different levels of risk across the prodromal phase. We separately 
investigated the ARMS individuals with a short or long duration of the ARMS. All these individuals 
fulfill the ARMS criteria (similar to the PACE criteria (Yung, et al. 1998)) at the time of scanning. In the 
first group (short-term ARMS, ARMS-ST) the scan was done at the time of ascertainment of the ARMS 
(within 3 months on average). According to published data the probability of developing psychosis in this 
groups is up to 20–40% over two years (Riecher-Rössler, et al. 2009; Yung, et al. 1998). In the second 
group (long-term ARMS, ARMS-LT) the scan was done on average 4.5 years of follow-up. Although at 
the time of the scan this group was still on the risk continuum to develop psychosis, according to the 
published data (Cannon, et al. 2008; Riecher-Rössler, et al. 2009; Yung, et al. 2007), the probability of 
developing subsequent psychosis was lower compared to ARMS-ST. Importantly, most of the ARMS 
individuals who made the transition (90.5%), did so in the first two years after the ARMS was 
ascertained. After these two years, only 3% of included ARMS individuals developed psychosis (Riecher-
Rössler, et al. 2009). In a study by Yung, the vast majority of transitions occurred in the first two years 
(estimated hazard ratio 0.58) and there were significantly less transitions over time (estimated hazard 
ratio 0.07) (Yung, et al. 2007).  
Our principal aim was to examine the neuroanatomical brain abnormalities associated with these two 
different transition probabilities. We also aimed at identifying putative neuroanatomical resilience factors 
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associated with a reduced risk of developing psychosis. Resilience, as the capacity to cope adequately 
with stressful events (Muller-Spahn 2008), was found impaired in psychotic individuals (van Os, et al. 
2005). Finally we aimed at clarifying the correlation between structural alterations and clinical outcomes 
during the prodromal phases of psychosis. 
 
METHODS  
The ARMS is defined according to the PACE (Personal Assessment and Crisis Evaluation Clinic, 
Melbourne) criteria and requires individuals to present attenuated positive psychotic or brief limited 
intermittent symptoms that do not reach full psychosis threshold (Riecher-Rössler, et al. 2009) and/or 
functional decline and genetic risk. Psychopathological symptoms mentioned above are often associated 
with negative symptoms (Lencz, et al. 2004; Riecher-Rössler, et al. 2009) and subtle cognitive deficits 
(Brewer, et al. 2006; Riecher-Rössler, et al. 2009; Simon and Umbricht 2010). Individuals with an ARMS 
(ARMS-ST) have a 20–40% probability of developing a psychosis (Riecher-Rössler, et al. 2009; Yung, et 
al. 1998). On a clinical basis only, it is very difficult to distinguish individuals who will later become 
psychotic from those who will not (McGorry, et al. 2003; Riecher-Rössler, et al. 2009). 
Sample instruments 
Since 1999, the Early Detection of Psychosis Clinic in Basel recruited and followed up the ARMS 
individuals over up to 7 years (Riecher-Rössler, et al. 2009). We assessed subjects using the ‘Basel 
Screening Instrument for Psychosis’ (BSIP), the Brief Psychiatric Rating Scale (BPRS), the Scale for the 
Assessment of Negative Symptoms (SANS) and the Global Assessment of Functioning (GAF) at the time 
of scanning. The BSIP evaluates ‘prodromal’ symptoms (according to DSM-III-R) occurring in the last 5 
years; nonspecific ‘prodromal’ signs  in the last 2 years; previous and current psychotic symptoms, 
psychosocial functioning over the last 5 years, substance dependency; and psychotic disorders among first 
and second degree relatives . We obtained current and previous psychotropic medication, alcohol, 
nicotine, cannabis, and other illegal drug consumption using a semi-structured interview adapted from 
Early Psychosis Prevention and Intervention Centre (EPPIC) Drug and Alcohol Assessment Schedule 
(www.eppic.org.au).  
 
Study population 
Inclusion to the ARMS required one or more of the following: a) "attenuated" psychotic symptoms b) 
brief limited intermittent psychotic symptoms (BLIPS) or c) a first-degree relative with a psychotic 
disorder plus a marked decline in social or occupational functioning. 
Exclusion criteria were: history of previous psychotic disorder; psychotic symptomatology secondary to 
an ‘organic’ disorder; substance abuse according to ICD-10 research criteria; psychotic symptomatology 
associated with an affective psychosis or a borderline personality disorder; age under 18 years; inadequate 
knowledge of the German language; and IQ less than 70.  
We divided the ARMS individuals (n=34) into two subgroups depending on the duration of the ARMS 
status since the baseline assessment. Thus, our ARMS-ST group had the MRI scan as soon as practicable, 
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on average within 0.22 years (SD=0.43). The ARMS-LT group consists of individuals who did not 
convert to psychosis over a longer follow up period of on average 4.62 years (SD=2.06) after first 
ascertainment. At time of scanning all the ARMS-ST and ARMS-LT individuals still fulfilled the criteria 
according to Yung et al. for the ARMS (Yung, et al. 1998) but, because of the difference in duration of 
the ARMS, had different probabilities of developing psychosis (Cannon, et al. 2008; Riecher-Rössler, et 
al. 2009; Yung, et al. 2008).   
From the baseline assessment the ARMS-ST and ARMS-LT subjects were followed up by the clinical 
service and received psychiatric case management. At the time of the scanning all the ARMS individuals 
(from both groups) were antipsychotic-naïve, except for one ARMS-ST subject (olanzapine 2.5 mg/day 
during 4 months before the scan) and two ARMS-LT subjects (medicated at the time of the scan, 1 
zuclopenthixol 3x40 mg/day, and 1 aripiprazole 5mg/day, for unknown period prescribed for treatment of 
negative symptoms from their physician). Furthermore, 8 of ARMS-LT and 6 of ARMS-ST were 
receiving antidepressants at the time of the MRI scan. 
We recruited healthy volunteers (HC, n=22) from the same geographical area as the other subjects. All 
subjects were representative of the local population of individuals presenting with an ARMS in terms of 
age, gender, handedness, IQ, and alcohol and cannabis consumption. These individuals had no current 
psychiatric disorder, no history of psychiatric illness, head trauma, neurological illness, serious medical 
or surgical illness, substance abuse, and no family history of any psychiatric disorder as assessed by an 
experienced psychiatrist in a detailed clinical assessment.  
 
Data collection 
MRI data were collected as part of the FEPSY (Früherkennung von Psychosen - Early Detection of 
Psychosis) study that is described in detail elsewhere (Riecher-Rössler, et al. 2009). Briefly, we recruited 
subjects with an ARMS in our specialized clinic for the early detection of psychosis at the Psychiatric 
Outpatient Department, Psychiatric University Clinics Basel, Switzerland. All the ARMS individuals 
were assessed at baseline and at the time of MRI scan.  
Data analysis 
Expanding on previous VBM studies in ARMS (meta-analysis (Fusar-Poli, et al. 2011)), here we 
investigated an ARMS-LT group with a lower probability of developing psychosis compared to the 
ARMS-ST group (Yung, et al. 2007). Additionally, we focused on the association between gray matter 
volume (GMV) and clinical measures. 
On the basis of previous findings, we tested the following hypotheses: 
1. The magnitude of volumetric abnormalities would be in parallel with the clinical status (ARMS-
LT<ARMS-ST) compared to the healthy control (HC) group.  
2. Regions with different gray matter volume in ARMS-LT compared to ARMS-ST would be associated 
with resilient factors playing a protective role in the process of psychosis.  
3. Significant correlations between GMV and psychotic symptoms or global functioning were expected in 
the regions showing volumetric differences in ARMS.  
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Magnetic resonance image acquisition 
Structural MRI 
3D T1-weighted MPRAGE sequence on a 3T scanner (Siemens Magnetom Verio, Siemens Healthcare, 
Erlangen, Germany) was applied with 1x1x1 mm3 isotropic spatial resolution and with inversion time of 
1000ms, TR of 2s and TE of 3.4ms. All the scans were screened for gross radiological abnormalities by 
an experienced neuroradiologist.  
 
Image analysis 
We examined group-related differences in gray matter volume using the SPM8 software 
(http://www.fil.ion.ucl.ac.uk/spm; Wellcome Department of Cognitive Neurology, London, United 
Kingdom) running under Matlab 7.1 (Math Works, Natick, MA, USA). T1-weighted MPRAGE images 
were pre-processed using the VBM8 toolbox (http://dbm.neuro.uni-jena.de/vbm8/).  This approach 
involves the creation of a study-specific template and the segmentation of each individual image using 
such template, with the aim of maximizing accuracy and sensitivity (Yassa and Stark 2009). We provided 
following steps: (1) checking for scanner artifacts and gross anatomical abnormalities for each subject; 
(2) using New Segmentation approach with different treatment of the mixing proportions; (3) using the 
DARTEL toolbox to produce a high-dimensional normalization protocol (Ashburner 2007); (4) checking 
for homogeneity across the sample; and (5) using 8 mm standard smoothing. We identified 2 subjects 
with mean covariance below two standard deviations and afterwards carefully screened their volumes, but 
found no artifacts and the quality of images was reasonable. We repeated the analyses without these two 
subjects, with the same results. That is why we decided not to exclude them from the analysis. After this 
pre-processing, we obtained segmented, normalized, and smoothed data that were used for the statistical 
analysis.  
We performed an analysis of covariance (ANCOVA) to compare gray matter images from all 3 groups 
(ARMS-ST, ARMS-LT, HC). We modeled age, gender, and total gray matter volume as covariates of no 
interest to reduce the potential impact of these variables on the findings. Statistical significance was 
assessed at cluster-level using the non-stationary random field theory (Hayasaka, et al. 2004). The first 
step of this cluster-level inference strategy consisted of identifying spatially contiguous voxels at a 
threshold of p<0.01, uncorrected (cluster-forming threshold) (Petersson, et al. 1999). Statistical inferences 
were then made at p<0.05 after family-wise error (FWE).  
To label the regions of brain activation MNI coordinates were transformed into Talairach space 
(www.ebire.org/hcnlab/cortical-mapping; Talairach Daemon software). 
 
Correlation of GMV and clinical data 
In addition to the whole-brain VBM analysis, correlation analyses were used to examine associations 
between GMV in areas where we found between-group volumetric differences. In order to examine the 
association between positive and negative symptoms and global functioning, we extracted gray matter 
values from the peak voxels (40 -18 6 and -56 -36 27) and from four subsidiary clusters with sphere 2mm 
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and performed a series of 2-tailed Pearson’s correlation analyses using Statistical Package for the Social 
Sciences (SPSS 19.0) (supplementary table). Statistical threshold was set at p<0.05. 
 
Statistical analysis of demographic data 
We examined clinical and socio-demographic differences between groups using one-way analysis of 
variance (ANOVA), F-test, or chi-square test (Table 1). For post-hoc analyses we used multiple two-
sided t-tests with Bonferroni correction. Statistical analyses were performed with the SPSS 19.0 and the 
level of significance was set at p<0.05. 
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Table 1: Demographic and clinical characteristic. 
Characteristic ARMS-ST (n=18) ARMS-LT 
(n=16) 
HC (n=22) Statistics 
Gender male (%) 14 (77.78%) 11 68.80%) 10 (45.45%) χ2=4.790 P=0.091 
Mean age years 25.11 (6.15) 25.06 (2.30) 26.86 (4.00) F=1.054 P=0.356 
Handedness (left) 0 1 (6.25%) 1 (4.54%) χ2=1.061 P=0.588 
MWT-B IQ 112 (14.13) 106 (12.38) 114 (9.45) F=1.969 P=0.151 
Years since presentation 0.22 (0.43) 4.62 (2.06) 0 F=78.590 P<0.000
1 Antipsychotics 0 (0%) 2 (12.50%) 0 (0%) χ2= 5.185 P=0.075 
Antidepressants 6 (33.33%) 8 (50.00%) 0 (0%) χ2=13.33
0 
P=0.001 
Cigarettes/day 8.25 (9.89) 8.94 (11.86) 3.50 (6.76) F=1.948 P=0.153 
Alcohol currently    χ2=5.044 P=0.283 
no 2 (11.11%) 2 (12.50%) 1 (4.54%)   
moderate 7 (38.89%) 8 (50.00%) 16 (72.72%)   
drunkenness 9 (50.00%) 6 (37.50%) 5 (22.73%)   
Cannabis 7 (38.89%) 5 (31.25%) 4 (18.18%) χ2=2.509 P=0.285 
BPRS total 40.06 (8.14) 32.67 (6.32) 24.55 (1.14) F=35.980 P<0.000
1 Post-hoc >HC: P<0.0001 >HC: P<0.0001    
 > ARMS-LT: P=0.001     
BPRS 9 2.47 (1.23) 1.73 (0.80) 1 (0) F=16.020 P<0.000
1 Post-hoc >HC: P<0.0001 >HC: P=0.027    
 > ARMS-LT: P=0.038     
BPRS 10 1.94 (1.20) 1.33 (0.90) 1 (0) F=6.370 P=0.003 
Post-hoc >HC: P=0.002     
BPRS 11 2.29 (1.40) 1.53 (0.83) 1 (0) F=9.930 P<0.000
1 Post-hoc >HC: P<0.0001     
BPRS 15 1.65 (1.12) 1.27 (0.80) 1 (0) F=3.560 P=0.031 
Post-hoc >HC: P=0.031     
APS 8.35 (3.32) 5.87 (2.26) 4 (0) F=18.710 P<0.000
1 Post-hoc >HC: P<0.0001 >HC: P=0.044    
 > ARMS-LT: P=0.007     
SANS total 21.00 (13.13) 10.53 (15.20) 0 F=18.080 P<0.000
1 Post-hoc >HC: P<0.0001 >HC: P=0.016    
 >ARMS-LT: P=0.026     
GAF 61.29 (11.80) 75.33 (14.86) 88.27 (4.29) F=32.880 P<0.000
1 Post-hoc <HC: P<0.0001 <HC: P=0.003    
 <ARMS-LT: P=0.001     
  
Demographic and clinical characteristics with mean values and standard deviations in parentheses. For post-hoc 
analyses the Bonferroni corrections (at P=0.05) in SPSS 19.0 were calculated. 
Abbreviations: APS - attenuated psychotic symptoms (APS = BPRS9 + BPRS10 + BPRS11 + BPRS15); BPRS 
– Brief Psychiatric Rating Scale: BPRS9 – suspiciousness, BPRS10 – hallucinations, BPRS11 – unusual thought 
content, BPRS15 – conceptual disorganization; GAF – Global Assessment of Functioning; MWT-B - multiple 
choice vocabulary IQ test (Mehrfachwahl-Wortschatz-Test Form B); SANS – Scale for the Assessment of 
Negative Symptoms 
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Table 2: Group differences in brain structure. 
Contrast P FWE 
corr. 
Cluster 
size 
P uncorr. T MNI 
x y z 
Region 
ARMS-ST < ARMS-LT 0.036* 2532 0.001** 4.21 40 -18 6 R insula, BA 13 
     54 -15 0 R STG, BA 22 
     58 -6 -6 R MTG, BA 21 
 0.401 1240 0.013 4.13 56 3 -24 R MTG, BA 21 
     44 3 -32 R MTG, BA 21 
 0.256 1484 0.008** 3.80 -56 -36 27 L IPL, BA 40 
     -63 -42 42 L IPL, BA 40 
     -46 -31 21 L Insula, BA 13 
ARMS-ST>ARMS-LT 0.709 882 0.032 3.64 38 26 18 R IFG 
     50 17 30 R MFG (BA 44, 45) 
     48 26 16 R MFG (BA 45) 
ARMS-ST < HC 0.475 1143 0.017 4.05 -34 44 24 L MFG, BA 10 
     -32 56 21 L SFG, BA 10 
     -28 29 27 L MFG, BA 9 
 0.139 1806 0.004** 3.76 -3 18 -23 L Rectal G, BA 11 
     2 21 -17 R Scal G, BA 25 
     6 33 -17 R Scal, PAC G, BA 
11 ARMS-LT>HC 0.235 1530 0.007** 4.02 36 -19 6 R insula 
     34 -25 24 R Insula, BA 13 
     39 -22 15 R Insula, BA 13 
 0.549 1056 0.021 3.54 54 4 -24 R MTG, STG, BA 21 
     46 20 -41 R STG, BA 38 
     57 14 -32 R STG, BA 38 
All ARMS < HC 0.460 1162 0.016 4.54 -30 30 27 L MFG, BA 9 
     -32 56 21 L SFG, BA 10 
     -33 45 22 L MFG, BA 10 
 
Group differences in gray matter volume calculated from full factorial ANCOVA analysis using SPM8 
with VBM8 toolbox with covariates age, gender, and VBM-GMV. 
There were no significant differences in contrasts: ARMS-ST >ARMS-LT, ARMS-ST>HC, ARMS-LT<HC, 
ARMS-ST+ARMS-LT > HC. 
* P value family-wise error (FEW) corrected P<0.05; ** P value uncorrected P<0.01 
Abbreviation: ARMS-LT – long-term ARMS; ARMS-ST – short-term ARMS; BA – Brodmann area, HC – 
healthy controls; IPL – inferior parietal lobule, IFG – inferior frontal gyrus, MFG – middle frontal gyrus, MTG – 
middle temporal gyrus, PAC G –paracingulate gyrus, PL – parietal lobe, Scal G – subcallosal gyrus, SFG – 
superior frontal gyrus, STG – superior temporal lobe, WM- white matter 
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RESULTS 
 
Clinical and demographic characteristics 
There were no significant differences between the ARMS-ST, ARMS-LT and HC in age (P=0.356), 
gender (P=0.091), handedness (P=0.588), IQ (P=0.151), current alcohol (P=0.283) and cannabis 
(P=0.285) use. There were significant between group differences in positive and negative symptoms and 
in global functioning: The ARMS-ST group showed a higher total BPRS (P=0.001), attenuated psychotic 
symptoms (APS, P=0.007) and SANS (P=0.026) and lower GAF (P<0.001) scores compared to the 
ARMS-LT group. Both ARMS groups differed in these measures compared to the HC group 
significantly. 
 
Gray matter volumes (VBM results) 
Volumetric abnormalities in the ARMS vs. HC 
The whole group of ARMS individuals compared to the HC showed less GMV in the left middle and 
superior frontal gyrus (table 2, P<0.05, uncorrected). The ARMS-ST group had less GMV than HC in the 
right subcallosal, paracingulate and left rectal gyri (table 2, P<0.01, uncorrected) and in the left middle 
and superior frontal gyrus (table 2, P<0.05, uncorrected). There were no regions where ARMS-ST had 
more GMV than HC. The ARMS-LT group had more GMV than the HC group in the right insula (table 
2, P<0.01, uncorrected) and in the right middle and superior temporal gyrus (table 2, P<0.05, 
uncorrected). There were no regions were the ARMS-LT had less GMV than HC. 
 
Volumetric abnormalities in the ARMS-LT vs. ARMS-ST 
Compared to the ARMS-LT, the ARMS-ST group had less GMV in the right insula extending into the 
right superior and middle temporal gyrus (table 2, P<0.05, FWE corrected, figure 1 panel A) and in the 
left parieto-insular region (table 2, P<0.01, uncorrected, figure 1 panel B), and in the right middle 
temporal gyrus (table 2, P<0.05, uncorrected). The ARMS-ST had more GMV in the right inferior and 
middle frontal gyrus compared to the ARMS-LT (table 2, P<0.05, uncorrected). 
 
Volumetric abnormalities across the three groups 
The direct comparison of GMV in the right insula (40 -18 6) across all three groups showed that the 
ARMS-ST group had less GMV than the HC and the HC less than the ARMS-LT (ARMS-
ST<HC<ARMS-LT).  
 
Correlation analyses of GMV and clinical outcomes 
Within the whole ARMS group (ARMS-LT+ARMS-ST) there was a negative correlation (P<0.05) 
between negative symptoms (SANS score) and GMV in the right insula (40 -18 6, Pearson’s correlation 
coefficient -0.376, figure 1), left insula (-46 -31 21, Pearson’s correlation coefficient -0.445, figure 1), 
and in the left inferior parietal lobule (-56 -36 27, Pearson’s correlation coefficient -0.381, supplementary 
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table). Functional decline (GAF score) correlated positively (P<0.01) with GMV in the right insula (40 -
18 6, Pearson’s correlation coefficient 0.446, figure 1), in the right superior temporal gyrus (54 –15 0, 
Pearson’s correlation coefficient 0.451; 58 -6 -6, Pearson’s correlation coefficient 0.348 at P<0.05) and in 
the left insula (-46 -31 21, Pearson’s correlation coefficient 0.466, figure 1) within the whole ARMS 
group. We found no significant correlations between positive symptoms (BPRS score) and GMV 
(supplementary table). When the above correlations were repeated within the ARMS-LT and ARMS-ST 
we found a significant relationship only between GMV and GAF (P<0.05): negative correlation in the 
ARMS-ST group in the left inferior parietal lobule (-56 -36 27, Pearson’s correlation coefficient -0.495, 
supplementary table) and positive correlation in the ARMS-LT group in the left insula and superior 
temporal gyrus (-46 -31 21, Pearson’s correlation coefficient 0.612, supplementary table). 
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Figure 1: Correlation of psychopathology and GMVs within the ARMS group. 
A       B 
 
 
 
Correlation of psychopathology and gray matter volume (GMV) in two large clusters with less GMV in the 
ARMS-ST compared to the ARMS-LT.  
The figures show the volumetric differences between ARSM-ST and ARMS-LT groups. The cluster in the figure 
above (A) comprising the right insula (40 -18 6) and extending into the right superior temporal gyrus (-50 -15 0) and 
right middle temporal gyrus (58 -6 -6) reflect decreased GMV in the ARMS-ST as compared to the ARMS-LT 
group (P<0.05 FEW corr.). Correlation of psychopathology and GMV in this cluster across the whole ARMS 
sample (ARMS-LT+ARMS-ST) (Pearson’s correlation coefficient for SANS -0.376* and for GAF 0.446**) is 
shown in the middle diagram on the left. 
The cluster in the bellow figure (B) comprising the left inferior parietal lobule (-56 -36 27 and -63 -42 42) and the 
left insula (-46 -31 21) reflect decreased GMV in the ARMS-ST as compared to the ARMS-LT group (P<0.01 
uncorr.). Correlation of psychopathology and GMV in this cluster across the whole ARMS sample (ARMS-
LT+ARMS-ST) (Pearson’s correlation coefficient for SANS -0.445* and for GAF 0.466**) is shown in the middle 
diagram on the right. The left side of the brain is shown on the left side of the images. 
 
* Significance at the niveau 0.05 2-tailed 
** Significance at the niveau 0.01 2-tailed 
Abbreviations: ARMS-LT – long-term ARMS; ARMS-ST – short-term ARMS; BPRS – Brief Psychiatric Rating 
Scale; GAF – Global Assessment of Functioning; HC - healthy controls; SANS – Scale for the Assessment of 
Negative Symptoms  
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Supplementary table: Correlation of psychopathology and GMVs. 
Cluster Score 
Pearson’s correlation coefficient 
ARMS ARMS-ST ARMS-LT 
R insula (40 -18 6) BPRS -0.210 0.465 -0.231 
 APS -0.107 0.152 0.306 
 SANS -0.376* 0.041 -0.408 
 GAF 0.446** -0.185 0.503 
R STG (54 -15 0) BPRS -0.307 0.268 -0.269 
 APS -0.214 0.241 -0.189 
 SANS -0.330 -0.368 -0.038 
 GAF 0.451** 0.286 0.177 
R STG (58 -6 -6) BPRS -0.265 0.094 -0.026 
 APS -0.114 0.394 -0.037 
 SANS -0.270 -0.383 0.080 
 GAF 0.348* 0.070 0.084 
L IPL (-56 -36 27) BPRS -0.290 0.192 -0.196 
 APS -0.210 0.058 0.075 
 SANS -0.381* -0.037 -0.349 
 GAF 0.335 -0.495* 0.447 
L IPL (-63 -42 42) BPRS -0.174 0.086 0.275 
 APS -0.2279 -0.188 0.145 
 SANS -0.099 0.257 0.125 
 GAF 0.197 -0.456 0.041 
L STG, insula (-46 -31 21) BPRS -0.259 0.401 -0.382 
 APS -0.176 0.190 -0.090 
 SANS -0.445* -0.104 -0.469 
 GAF 0.466** -0.233 0.612* 
 
Correlation of psychopathology and gray matter volume (GMV) in 2 large clusters with less GMV 
in the ARMS-ST compared to the ARMS-LT.  
* Significance level 0.05, 2-tailed 
** Significance level 0.01, 2-tailed 
 
Abbreviations: APS - attenuated psychotic symptoms (APS = BPRS9 + BPRS10 + BPRS11 + BPRS15); 
ARMS-LT – long-term ARMS; ARMS-ST – short-term ARMS; BPRS – Brief Psychiatric Rating Scale: 
BPRS9 – suspiciousness, BPRS10 – hallucinations, BPRS11 – unusual thought content, BPRS15 – 
conceptual disorganization; GAF – Global Assessment of Functioning; HC - healthy controls; IPL – 
inferior parietal lobule; SANS – Scale for the Assessment of Negative Symptoms; STG – superior 
temporal gyrus 
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DISCUSSION 
Main findings 
We used structural MRI to examine individuals at high clinical risk of psychosis. The ARMS subjects 
were divided into two groups according to different duration of ARMS and probability for transition to 
psychosis. 
In line with previous MRI studies (meta-analyses (Fusar-Poli, et al. 2011; Smieskova, et al. 2010)) we 
found that both ARMS-ST and ARMS-LT individuals had volumetric abnormalities relative to HCs. 
These alterations can be interpreted as state-marker risk factors for the disease and are qualitatively 
similar to those seen in patients with schizophrenia (meta-analyses (Ellison-Wright and Bullmore 2010; 
Glahn, et al. 2008)). However, we found more prefrontal, insular and middle temporal volumetric 
reductions in the ARMS-ST group, as compared to the ARMS-LT and HC group, in line with structural 
deficits in high-risk individuals with later transition to psychosis  (meta-analysis (Smieskova, et al. 
2010)). By comparing the three groups we found differences of the right insular volume (ARMS-ST, HC, 
ARMS-LT) what could be associated with some resilience factors. At a symptoms level we showed that 
negative symptoms correlated negatively and global functioning positively with GMV in specific brain 
areas within the ARMS subjects.  
 
Vulnerability-associated volumetric differences 
Comparing ARMS-ST and HC revealed that vulnerability to psychosis was associated with orbital and 
middle frontal volumetric reductions. Comparing ARMS-LT and HC revealed more GMV in right insulo-
temporal regions. These findings are similar to the published volumetric abnormalities found in ARMS  
(meta-analysis (Fusar-Poli, et al. 2011)). Compared to ARMS-LT individuals, ARMS-ST showed 
reduced GMV in the insula bilaterally, corresponding to the reductions seen in ARMS who later transit to 
psychosis (Borgwardt, et al. 2007a; Pantelis, et al. 2003a; Takahashi, et al. 2009b). 
  
Volumetric differences associated with different transition probability  
There was a difference in GMV reduction between ARMS-ST and ARMS-LT. ARMS-ST individuals 
had decreased GMV in one cluster in the right insula and middle temporal gyrus and the other one in the 
left inferior parietal lobule and insula as compared to the ARMS-LT group. Such alterations may 
represent the neurobiological substrate of the different transition probability within the ARMS. In line 
with this interpretation, these regions were reduced in ARMS with subsequent transition to psychosis as 
compared to those without transition (Fusar-Poli, et al. 2011; Smieskova, et al. 2010). Furthermore, 
previous investigations have shown that GVM alterations in some of the above regions may be directly 
associated with the consistent neurofunctional alterations observed in the ARMS during cognitive tasks 
(Fusar-Poli, et al. 2010c). 
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Volumetric differences associated with resilience? 
The ARMS-LT subjects showed more right insular volume compared to the ARMS-ST. Interestingly, this 
GMV increase was detectable not only in the ARMS-LT compared to the ARMS-ST, but as well to the 
HC group. It is possible that the insular GMV increase may represent activity-related hypertrophy 
(Draganski, et al. 2006) secondary to neurofunctional activation of insular areas when experiencing 
psychotic symptoms (O'Daly, et al. 2007). Additionally, we could see here some protective processes. 
The ARMS individuals differ from each other in the duration and severity of their symptoms, and in their 
vulnerability to transit to psychosis. Those who are more vulnerable to transit to psychosis might have 
less resilience factors and vice versa. Some ARMS might have better internal resources, attitudinal 
approaches and overall functioning (as in unmedicated patients with schizophrenia (Harrow and Jobe 
2007)) and can recover from the ARMS subsequently (Simon and Umbricht 2010). Some of the ARMS 
individuals might be on the ARMS continuum for a longer period of time, like our ARMS-LT subjects 
still fulfilling the ARMS criteria. Strikingly, right posterior insular abnormalities play an important role in 
the lack of intero-ceptive insight (Palaniyappan, et al. 2010) and worse functional outcome in 
schizophrenia (Mohamed, et al. 2009). Thus the awareness of the illness with positive relationship to the 
recovery (Lysaker, et al. 2007) could be one of the resilience factors associated with insular volume 
increase (Lappin, et al. 2007). 
 
Clinical implications 
The mean duration of the ARMS was 4.5 years in the ARMS-LT group; the probability that any of these 
subjects will develop psychosis in the future is low (Cannon, et al. 2008; Riecher-Rössler, et al. 2009). In 
the ARMS-ST subjects, we expect a transition rate of approximately 20-40% (Riecher-Rössler, et al. 
2009) in the next one to two years. This allows the investigation of vulnerability and higher transition 
probability associated changes in brain activation in the ARMS-ST compared to the HC. Interestingly, 
our ARMS-LT did not differ from the ARMS-ST in age. This could be because of small sample sizes and 
needs further investigation. On the other hand, the differences between ARMS-ST and ARMS-LT are not 
solely attributable to the difference in age between those groups. 
The structural abnormalities we found were not directly attributable to antipsychotic treatment, as all of 
the ARMS-ST individuals were antipsychotic-naïve and only 2 ARMS-LT individuals had antipsychotic 
treatment at the time of scanning. The influence of antipsychotics on the brain function is not entirely 
clear, however antipsychotics may affect GMV (Ho, et al. 2011a). Furthermore, both individuals were 
treated with atypical neuroleptics in very low doses. Consequently we argue that the volumetric 
differences between these two groups reflect both disrupted brain structure and protective processes, as 
discussed above. It remains unknown, whether structural abnormalities are reversible or compensatory in 
their nature. Some recent studies reported reversibility of prodromal symptoms, especially in adolescent 
high risk group (Simon and Umbricht 2010).  
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Correlation with clinical outcomes 
We proved partially our second hypothesis of correlation between volumetric differences and psychotic 
symptoms. Negative symptoms correlated negatively with the GMV reduction in the insula and left 
parietal regions within our whole ARMS population. However, positive symptoms did not correlate with 
the GMV changes at all. Previous studies have found negative correlations between positive symptoms 
and GMV (Crespo-Facorro, et al. 2000; Pressler, et al. 2005) as well as no correlation (Crespo-Facorro, et 
al. 2010) in schizophrenia. 
As opposed to that, reduced GMV in the bilateral insula and in the right superior and middle temporal 
gyrus positively correlated with functional decline within the whole ARMS group. This is in line with a 
previous study indicating that the duration of prodromal symptoms predicts the longitudinal GAF scores 
in subjects with an ARMS (Fusar-Poli, et al. 2009b). 
 
Limitations 
Some limitations of this study should be considered. Firstly, although the ARMS-ST group has a 20-40% 
probability of transition to psychosis, there is a high false positive probability of approximately 60-80%. 
That could be the reason, why we found the differences with relatively low significance in the group 
comparison. These between group differences could be more pronounced in the pure transition group. 
Secondly, we found no significant correlation between clinical and structural measures in our ARMS-ST 
and ARMS-LT subgroups, only within the whole ARMS group. This could be caused by the small 
sample sizes. However, we examined especially those regions with relative structural differences between 
the groups. Thirdly, a large portion of the ARMS-ST individuals could become ARMS-LT in several 
months, and with the aim to investigate longitudinal differences in the same individuals, we should scan 
them then again in 4.5 years. Fourthly, the use of VBM methodology brings problems of brain 
registration and the size of the smoothing kernel. This is relevant especially when relatively small 
differences are expected, as it is the case in ARMS individuals. The exact meaning of volumetric 
abnormalities (exaggerated dendritic pruning, impaired myelination, apoptosis or neuropil changes) is not 
entirely clear. All the same, this technique allows the comparison of the entire brain volumes at the single 
voxel level, and we used the improved segmentation and normalization SPM8 protocols (Yassa and Stark 
2009) in our analyses.  
 
Conclusions 
Structural alterations in subjects at high clinical risk for psychosis are associated with negative symptoms 
and impairment in global functioning. Specific gray matter volume abnormalities within the ARMS may 
distinguish different transition probabilities and resilience factors. In particular, volume loss in the insula 
is associated with a higher risk for transition to psychosis.  
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ABSTRACT 
Objectives: Neurofunctional alterations are correlates of vulnerability to psychosis, as well as of the 
disorder itself. How these abnormalities relate to different probabilities for later transition to psychosis is 
unclear. We investigated vulnerability- versus disease-related versus resilience biomarkers of psychosis 
during working memory processing in individuals with an at-risk mental state (ARMS).  
Experimental design: Patients with ‘first-episode psychosis’ (FEP, n=21), short-term ARMS (ARMS-
ST, n=17), long-term ARMS (ARMS-LT, n=16), and healthy controls (HC, n=20) were investigated with 
an n-back working memory task. We examined functional (fMRI) and structural magnetic resonance 
imaging (sMRI) data in conjunction using Biological Parametric Mapping (BPM) toolbox. 
Principal observations: There were no differences in accuracy, but the FEP and the ARMS-ST group 
had longer reaction times compared to the HC and the ARMS-LT group. With the 2-back>0-back 
contrast we found reduced functional activation in ARMS-ST and FEP compared to the HC group in 
parietal and middle frontal regions. Relative to ARMS-LT individuals, FEP patients showed decreased 
activation in the bilateral inferior frontal gyrus and insula, and in the left prefrontal cortex. Compared to 
the ARMS-LT, the ARMS-ST subjects showed reduced activation in the right inferior frontal gyrus and 
insula. Reduced insular and prefrontal activation was associated with gray matter volume reduction in the 
same area in the ARMS-LT group.  
Conclusions: These findings suggest that vulnerability to psychosis was associated with neurofunctional 
alterations in fronto-temporo-parietal networks in a working memory task.  Neurofunctional differences 
within the ARMS were related to different duration of the prodromal state and resilience factors. 
INTRODUCTION 
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Neurofunctional alterations are a leading feature of psychosis. To date, it is not clear to what extent these 
abnormalities correlate with vulnerability to psychosis or pathology of the disorder itself. However, for 
the understanding of their pathogeneses it is important to clarify their onset and time course of the 
dynamic neurobiological processes underlying the transition from a high-risk state to manifest psychosis.  
Working memory (WM) impairment is one of the most pronounced cognitive features found in 
schizophrenia (Callicott et al., 2003b; Cannon et al., 2005; Forbes et al., 2009; Glahn et al., 2005; Jansma 
et al., 2004; Johnson et al., 2006; Manoach et al., 2000; Menon et al., 2001; Schneider et al., 2007). 
Impairments in the WM network activation depend on the individual performance (Ettinger et al., 2011), 
higher performing patients with schizophrenia showed hyper-activation and lower performing patients 
showed hypo-activation what was explained using the compensation model of activation (Sanz et al., 
2009). However, the relation of physiological and clinical variables (positive, negative symptoms) is 
complicated by the multidimensional nature of psychotic symptoms. Recent advances in psychiatric 
research indicate that neurocognitive deficits are also evident in subjects with an at-risk mental state 
(ARMS) (Eastvold et al., 2007; Pflueger et al., 2007; Simon et al., 2007; Smith et al., 2006) and in non-
affected first-degree relatives (Karch et al., 2009; Karlsgodt et al., 2007; Lee et al., 2010a; MacDonald et 
al., 2009; Meda et al., 2008; Spence et al., 2000).  
The ARMS is defined according to the PACE (Personal Assessment and Crisis Evaluation Clinic, 
Melbourne) criteria and requires individuals to present attenuated positive psychotic or brief limited 
intermittent symptoms that do not reach full psychosis threshold (Riecher-Rössler et al., 2007; Riecher-
Rössler et al., 2009; Yung et al., 2004) or functional decline. These psychopathological symptoms are 
often associated with negative (Lencz et al., 2004; Riecher-Rössler et al., 2009) symptoms, subtle 
cognitive deficits (Brewer et al., 2006; Riecher-Rössler et al., 2009) and include deficits in working 
memory function (Broome et al., 2010; Simon et al., 2007). Those with the ARMS have a 20–40% 
probability of developing the psychosis (Riecher-Rössler et al., 2007; Riecher-Rössler et al., 2009; Yung 
et al., 1998). Furthermore, neurofunctional deficits may be associated with transition to psychosis and 
thus can be seen as vulnerability markers for developing schizophrenia (Morey et al., 2005; Riecher-
Rössler et al., 2009).  
Over the past decade, structural (sMRI) and functional magnetic resonance imaging (fMRI) methods have 
been extensively employed to identify the anatomical and neurofunctional alterations in the pre-psychotic 
phases. In subjects at high-risk for psychosis, MRI studies showed structural abnormalities (Borgwardt et 
al., 2007a; Borgwardt et al., 2008; Borgwardt et al., 2006; Borgwardt et al., 2007b; Koutsouleris et al., 
2009; Meisenzahl et al., 2008; Pantelis et al., 2003; Witthaus et al., 2009) and neurofunctional deficits in 
the frontal and temporal task-related networks (Allen et al., 2010; Fusar-Poli et al., 2007a), especially 
during working memory tasks (Broome et al., 2010; Broome et al., 2009; Pauly et al., 2010). Such 
alterations are not only attributable to the effects of illness or treatment and may represent markers of 
vulnerability to psychosis (Smieskova et al., 2010).  
Since 1999, the Early Detection of Psychosis Clinic (FEPSY) in Basel recruited and followed up the 
ARMS individuals over up to 7 years (Riecher-Rössler et al., 2009). Importantly, 19 of those 21 ARMS 
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individuals who made transition, transit in the first two years after their ascertainment. Afterwards, only 2 
out of 53 included ARMS individuals made transition to psychosis (Riecher-Rössler et al., 2009) 
representing a reduced transition probability. Similarly, the vast majority of transitions occur in the first 
two years (estimated hazard ratio 0.58) and significantly dropped over time (estimated hazard ratio 0.07) 
(Yung et al., 2007). In the present study, we therefore investigated the ARMS individuals with a short or 
long duration of the ARMS. All these individuals fulfil the ARMS criteria (similar to the PACE criteria) 
at the time of scan. In the first group (short-term ARMS, ARMS-ST), the scan was done at the time of 
ascertainment of the ARMS (within 3 months on average). In the second group (long-term ARMS, 
ARMS-LT), the scan was done after 2 years, on average 4.5 years of follow-up with no transition to 
psychosis. At the time of the scan in the latter group, the assessment of the ARMS was repeated and 
PACE criteria were still met. We thus investigated two ARMS subgroups both representing vulnerability 
to psychosis with different probabilities of later transition to psychosis. It is important to emphasize that 
also ARMS-LT group continue to meet ARMS criteria at the time of scan. This group is therefore clearly 
on the risk continuum to develop psychosis, but according to the published data has lower probability to 
develop subsequent psychosis than ARMS-ST. In this context, we aimed to examine the neurofunctional 
brain abnormalities associated with higher vs. lower probability of developing psychosis. This could 
improve our understanding of the neurofunctional changes in the mental state in early stages in the 
context of clinical staging model (McGorry et al., 2009).  
Until now, there is a small number of fMRI studies in people with an ARMS (Broome et al., 2010; 
Broome et al., 2009; Fusar-Poli et al., 2010a; Fusar-Poli et al., 2010b) investigating neurofunctional 
abnormalities while performing a working memory task. Expanding the previous study (Broome et al., 
2009), here we investigated an ARMS-LT group with a lower probability of developing psychosis 
compared to the ARMS-ST group (Yung et al., 2007).  
Additionally, we focused on functional and structural differences between individuals with vulnerability 
to develop psychosis and already psychotic individuals (patients with first-episode psychosis, FEP).  
Thus, we specifically wanted to test vulnerability- versus disease-related versus resilience biomarkers of 
psychosis. 
On the basis of previous findings (Broome et al., 2009), we tested the following hypotheses: 
1. The WM-specific activation would be diminished in parallel with the clinical status (ARMS-
LT<ARMS-ST<FEP) compared to the healthy control (HC) group.  
2. The ARMS-ST group would show more functional deficits associated with volumetric abnormalities 
compared to the ARMS-LT group.  
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MATERIALS AND METHODS  
Subjects 
MRI data were collected as part of a research program on early detection of psychosis that is described in 
detail elsewhere (Riecher-Rössler et al., 2006). Briefly, we recruited subjects with an ARMS and patients 
experiencing a FEP in our specialized clinic for the early detection of psychosis at the Psychiatric 
Outpatient Department, Psychiatric University Clinics Basel, Switzerland.  
The entire group of individuals with an ARMS (ARMS-ST and ARMS-LT; n=33) corresponds to the 
criteria by Yung (Yung et al., 1998) employed in previous MRI studies (Borgwardt et al., 2007a; 
Borgwardt et al., 2007b; Pantelis et al., 2003; Sun et al., 2009; Takahashi et al., 2009a; Takahashi et al., 
2009b; Velakoulis et al., 2006; Walterfang et al., 2008; Wood et al., 2003; Wood et al., 2005). All the 
ARMS individuals were assessed at the time of MRI scan. Inclusion thus required one or more of the 
following a) "attenuated" psychotic symptoms b) brief limited intermittent psychotic symptoms (BLIPS) 
or c) a first degree relative with a psychotic disorder plus at least two indicators of a clinical change, such 
as a marked decline in social or occupational functioning. 
We divided the ARMS individuals into two subgroups depending on the duration of the ARMS status 
since its first presentation. The ARMS-ST group had the MRI scan as soon as practicable, on average 
within 3 months after ascertainment. The ARMS-LT group comprise of individuals who did not convert 
to psychosis over a longer follow up period of on average 4.5 years after first ascertainment. The mean 
duration of follow up of ARMS-ST subjects was 2.88 months (SD=5.24), with one individual who 
developed psychosis. The mean follow up time since presentation in ARMS-LT subgroup was 55.44 
months (SD=24.72). The range for the follow-up time since presentation was 0-17 months in the ARMS-
ST group and 27-96 months in the ARMS-LT group. At time of scanning all the ARMS-ST and ARMS-
LT individuals still fulfilled the criteria by Yung et al. for ARMS (Riecher-Rössler et al., 2008; Yung et 
al., 1998) but had different probabilities of developing psychosis (Cannon et al., 2008; Riecher-Rössler et 
al., 2009; Yung et al., 2008).   
During follow-up, the ARMS-ST and ARMS-LT subjects received psychiatric case management without 
any antipsychotic treatment. All the ARMS individuals (from both groups) were antipsychotic-naïve. 
However, the general practitioners had treated the minority of them: one subject was at the time of 
scanning antipsychotic-free (olanzapine 2.5 mg/day for 9 months; 4 months before the scan) and two 
ARMS-LT subjects were currently medicated (1 zuclopenthixol 3x40 mg/day, and 1 aripiprazole 
5mg/day, for unknown period prescribed for treatment of negative symptoms). Furthermore, 8 of ARMS-
LT and 6 of ARMS-ST were receiving antidepressants at the time of the MRI scan. The small amount of 
individuals receiving antidepressant precluded analysis of putative neurofunctional effect of 
antidepressants (Fusar-Poli et al., 2007b). 
The FEP patients (n=21) were defined as subjects who met the operational criteria for ‘first-episode 
psychosis’(Breitborde, 2009). Inclusion required scores of 4 or above on the hallucination item or 5 or 
above on the unusual thought content, suspiciousness or conceptual disorganization items of the BPRS 
(Yung et al., 1998). The symptoms must have occurred at least several times a week and persisted for 
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more than one week. Most of our FEP patients were not receiving medication (7 of them antipsychotic-
naïve, 6 antipsychotic-free) at time of scanning. Eight FEP patients were receiving antipsychotics at the 
time of scanning for approximately 2 months (5 quetiapine and 2 paliperidone for less than 6 months, 1 
olanzapine for less than 2 years).   
We assessed subjects using the ‘Basel Screening Instrument for Psychosis’ (BSIP) (Riecher-Rössler et al., 
2008; Riecher-Rössler et al., 2007), the Brief Psychiatric Rating Scale (BPRS)(Lukoff et al., 1986), the 
Scale for the Assessment of Negative Symptoms (SANS)(Andreasen, 1989) and the Global Assessment 
of Functioning (GAF). The BSIP evaluates ‘prodromal’ symptoms (defined according to the Diagnosis 
and Statistical Manual of Mental Disorder, DSM-III-R) occurring in the last 5 years; nonspecific 
‘prodromal’ signs (Riecher-Rössler et al., 2007) in the last 2 years; previous or current psychotic 
symptoms, psychosocial functioning over the last 5 years, substance dependency; and psychotic disorders 
among first and second degree relatives (Riecher-Rössler et al., 2008) . We obtained current and previous 
psychotropic medication, alcohol, nicotine, cannabis, and other illegal drug consumption using a semi-
structured interview adapted from Early Psychosis Prevention and Intervention Centre (EPPIC) Drug and 
Alcohol Assessment Schedule (www.eppic.org.au).  
We applied the following exclusion criteria to both these groups: history of previous psychotic disorder; 
psychotic symptomatology secondary to an ‘organic’ disorder; substance abuse according to ICD-10 
research criteria; psychotic symptomatology associated with an affective psychosis or a borderline 
personality disorder; age under 18 years; inadequate knowledge of the German language; and IQ (Lehrl et 
al., 1995) less than 70.  
We recruited healthy volunteers (HC, n=20) from the same geographical area as the other groups. All 
subjects were representative of the local population of individuals presenting with an ARMS or FEP in 
terms of age, gender, handedness, and alcohol and cannabis consumption. These individuals had no 
current psychiatric disorder, no history of psychiatric illness, head trauma, neurological illness, serious 
medical or surgical illness, substance abuse, and no family history of any psychiatric disorder as assessed 
by an experienced psychiatrist in a detailed clinical semi-structured interview. All participants provided 
written informed consent, and the study had research ethics committee permission. 
 
Magnetic resonance image acquisition 
Functional MRI 
We acquired the n-back task elicited images on a 3 T scanner (Siemens Magnetom Verio, Siemens 
Healthcare, Erlangen, Germany) using an echo planar sequence with a repetition time (TR) of 2.5 s, echo 
time (TE) of 28 ms, matrix 76x76, 126 volumes and 38 slices with 0.5 mm interslice gap, providing a 
resolution of 3x3x3 mm3, and a field of view (FOV) 228x228 cm2. With an inter-stimulus interval of 2 
seconds, all subjects saw the series of black letters on the white background in a prismatic mirror. Each 
stimulus was presented for 1 second. The size of the letters was 8 cm projected on the screen at the end of 
the scanner. All participants with myopia had the possibility to use plastic glasses and the readability was 
controlled always before the experiment started. During a baseline (0-back) condition, subjects were 
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required to press the button with the right hand when the letter „X” appeared. During 1-back and 2-back 
conditions, participants were instructed to press the button if the currently presented letter was the same 
as that presented 1 (1-back condition) or 2 (2-back condition) trials beforehand. The three conditions were 
presented in 10 alternating 30 s blocks (2 x 1-back, 3 x 2-back and 5 x 0-back) matched for the number of 
target letters per block (i.e. 2 or 3), in a pseudo-random order. The reaction times and response accuracy 
were recorded on-line.  
 
Structural MRI 
For anatomical imaging a 3D T1-weighted MPRAGE sequence was applied with 1x1x1 mm3 isotropic 
spatial resolution and with inversion time of 1000 ms, TR of 2 s and TE of 3.4 ms. All scans were 
screened for gross radiological abnormalities by an experienced neuroradiologist. Five individuals were 
not included to the analyses due to arachnoidal cysts, cavernom, cerebellar atrophy and T2 
hyperintensities (Borgwardt et al., 2006).  
 
Image analysis 
We analyzed functional MRI data using the Statistical Parametric Mapping software package (SPM8; 
Wellcome Department of Cognitive Neurology, London, United Kingdom). All volumes were realigned 
to the first volume, corrected for motion artefacts, mean adjusted by proportional scaling, normalized into 
standard stereotactic space (template provided by the Montreal Neurological Institute), and smoothed 
using a 8 mm full-width-at half-maximum (FWHM) Gaussian kernel. After exclusion of error trials, we 
convolved the onset times for each trial in seconds with a canonical hemodynamic response function.  
We pre-processed all structural images with the Voxel-Based Morphometry (VBM8) toolbox 
(http://dbm.neuro.uni-jena.de/vbm8/) implemented in SPM8. It utilizes New Segmentation and DARTEL 
methods in SPM8. We modulated the segmented tissue maps of gray matter (GM) with the Jacobian 
determinants from the spatial normalization to correct for volume changes. We chose the option 
’modulation of non-linear effects only‘, which equals the use of default modulation (of both affine and 
non-linear effects) and globally scaling data according to the inverse scaling factor due to affine 
normalization. Finally, we smoothed the modulated GM images with an 8-mm FWHM Gaussian kernel.  
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Integration of multimodal imaging data 
We chose the multimodal integrative image analysis to determine if brain abnormalities in working 
memory were associated with volumetric abnormalities in ARMS-ST, ARMS-LT and FEP individuals. 
We used Biological Parametric Mapping (BPM) (Casanova et al., 2007) toolbox, developed in Matlab 
and visualized our results in SPM8. Using 1st level 2-back>0-back contrast images, we provided BPM 
Analysis of covariance (ANCOVA) analyses with all 4 groups in one model. The fMRI data were the 
primary modality and the corresponding VBM data the imaging covariates. We evaluated the impact of 
the group structural differences on the fMRI data on a voxel-wise basis with gray matter volume (GMV) 
as a regressor. To account for age- and sex-specific associations (Elsabagh et al., 2009) we used age and 
gender as covariates in the ANCOVA model. We have run the integrative analyses twice, one with and 
one without GMV as covariate to find the regions where the group differences were lost due to this 
covariation. We chose 2-back>0-back contrasts as attention-independent modality with higher load level 
to search differences across groups. To specify the WM-associated network of activation, we used the 
‘main-effect of n-back task’ (full-factorial model; p<0.001, FWE-corrected) as a mask for 2nd level 
analyses. The correlation between the blood oxygen level-dependent (BOLD) signal and GMV was 
calculated on a voxel-by-voxel basis with the BPM correlation model (Casanova et al., 2007).  
Statistical significance in all analyses (VBM, fMRI and BPM) was assessed at the cluster-level using the 
non-stationary random field theory (Hayasaka et al., 2004). The first step of this cluster-level inference 
strategy consisted of identifying spatially contiguous voxels at a threshold of p<0.01, uncorrected 
(cluster-forming threshold) (Petersson et al., 1999). Finally, a family-wise error (FWE) corrected cluster-
extent threshold of p<0.05 was defined in order to infer statistical significance. To provide sufficient 
details about the present study, we followed the guidelines for reporting an fMRI study (Poldrack et al., 
2008). 
To label the regions of brain activation MNI coordinates were transformed into Talairach space 
(www.ebire.org/hcnlab/cortical-mapping; Talairach Daemon software; (Mai JK, 2008)). 
 
Statistical analysis of demographic data 
We examined clinical and socio-demographic differences between groups using one-way analysis of 
variance (ANOVA), F-test, or chi-square test (Table 1). For post-hoc analyses we used the least-
significant difference (LSD) correction. Statistical analyses were performed with the Statistical Package 
for the Social Sciences (SPSS 16.0). 
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RESULTS 
Clinical and demographic characteristics of the sample 
There were no significant differences among our groups with respect to age (P=0.177), gender (P=0.245), 
handedness (P=0.638), IQ (P=0.166), current alcohol (P=0.247) and cannabis (P=0.489) consumption. 
There were significant between group differences in positive and negative symptoms, and in global 
functioning over all our groups. The FEP group had more positive symptoms than ARMS-ST (P=0.006), 
ARMS-LT (P<0.001) and HC (P<0.001) groups. The ARMS-ST group showed a higher BPRS (P=0.018) 
and SANS (P=0.015) and a lower GAF (P<0.0001) score compared to the ARMS-LT (Table 1).  
 
N-back task performance 
There was no difference in the accuracy in any of conditions.  Reaction times were significantly longer in 
the FEP compared to the HC and ARMS-LT groups and in the ARMS-ST compared to the HC and 
ARMS-LT groups (Supplementary table 1). 
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Table 1: Demographic and clinical characteristics. 
Characteristic FEP (n=21) ARMS-ST (n=17) ARMS-LT (n=16) HC (n=20) Statistics 
Gender M/F, (male) 16/5 (76.2%) 13/4 (76.5%) 11/5 (68.8%) 10/10 (50.0%) P=0.245 χ2=4.154 
Mean age in yrs (SD) 28.57 (7.2) 25.24 (6.3) 25.06 (2.3) 26.50 (4.0) P=0.177 F=1.691 
Handedness (left) 2 (9.5%) 0 1 (6.2%) 1 (5%) P=0.638 χ2=1.697 
MWT-B_IQ 107 (14.2) 112 (14.1) 106 (12.4) 114 (9.8) P=0.166 F=1.749 
Years of education 
(SD) 13.35 (3.14) 13.80 (3.62) 13.88 (2.38) 
16.38 
(2.96) P=0.012 F=3.940 
Post-hoc FEP<HC: P=0.003 
ARMS-ST<HC: 
P=0.016 
ARMS-LT<HC: 
P=0.017    
Time since 
presentation (yrs) 
(SD) 
2.90 (2.84) 0.24 (0.437) 4.62 (2.06) 0 P<0.0001 F=18.135 
BPRS total score 
(SD) 49.20 (15.02) 40.30 (8.33) 32.31 (6.27) 
24.50 
(1.15) P<0.0001 F=24.783 
Post-hoc FEP>HC: P<0.0001 
ARMS-ST>HC: 
P<0.0001 
ARMS-LT>HC: 
P=0.015    
 FEP>ARMS-LT: P<0.001 
ARMS-ST<FEP: 
P=0.006 
ARMS-LT 
<ARMS-ST: 
P=0.018 
   
SANS total score 
(SD) 28.05 (16.20) 21.88 (13.04) 10.53 (15.20) 0 P<0.0001 F=18.132 
Post-hoc FEP>HC: P<0.0001 
ARMS-ST>HC: 
P<0.0001 
ARMS-LT>HC: 
P=0.018    
 FEP>ARMS-LT: P<0.001 
ARMS-ST>ARMS-
LT: P=0.015     
GAF (SD) 56.50 (14.32) 58.94 (12.63) 75.33 (14.86) 88.50 (4.44) P<0.0001 F=29.707 
Post-hoc FEP<HC: P<0.0001 
ARMS-ST<HC: 
P<0.0001 
ARMS-LT<HC: 
P=0.002    
 FEP<ARMS-LT: P<0.0001 
ARMS-ST<ARMS-
LT: P<0.0001     
Antipsychotics at 
MRI scan 8 (38%) 0 (0%) 2 (12.5%) 0 (0%) P=0.001 χ2= 16.653 
Antidepressants at 
MRI scan 8 (38.1%) 6 (35.3%) 8 (50.0%) 0 (0%) P=0.006 χ2=12.564 
Smoking 
cigarettes/day (SD) 13.33 (13.17) 8.15 (10.19) 8.94 (11.86) 2.85 (5.92) P=0.024 F=3.345 
Post-hoc FEP>HC: P=0.002      
Alcohol currently     P=0.274 χ2=7.538 
no 4 (19%) 2 (11.8%) 2 (12.5%) 1 (5.0%)   
moderate 10 (47.6%) 6 (35.3%) 8 (50.0%) 15 (75.0%)   
s.t. drunkenness 7 (33.3%) 9 (52.9%) 6 (37.5%) 4 (20.0%)   
Cannabis currently 7 (35.0%) 7 (43.8%) 5 (31.2%) 4 (20%) P=0.489 χ2=2.428 
 
Abbreviations: ARMS-ST – short-term ARMS; ARMS-LT – long-term ARMS; BPRS – Brief Psychiatric Rating Scale; 
GAF – Global Assessment of Functioning; HC - healthy controls; MWT-B - multiple choice vocabulary test 
(Mehrfachwahl-Wortschatz-Test Form B), FEP - ‘first-episode psychosis’; SANS – Scale for the Assessment of Negative 
Symptoms 
  
  76 
Supplementary table1: Behavioural data during n-back task. 
Characteristic FEP (n=21) ARMS-ST (n=17) ARMS-LT (n=16) HC (n=20) Statistics 
n-back errors (SD) 8.76 (9.2) 5.59 (6.2) 11.69 (11.7) 5.5 (7.6) P=0.133 F=1.926 
0-back errors (SD) 3.57 (5.0) 1.82 (3.5) 5.31 (5.8) 2.4 (4.0) P=0.149 F=1.836 
1-back errors (SD) 1.81 (2.0) 1.06 (1.6) 2.06 (2.5) 1.05 (1.6) P=0.283 F=1.294 
2-back errors (SD) 3.38 (3.2) 2.71 (2.2) 4.38 (4.0) 2.05 (2.4) P=0.129 F=1.953 
0-back tR (SD) 760.6 (84.4) 709.8 (88.9) 659 (107.0) 
640.4 
105.9) 
P=0.002 F=5.474 
1-back tR (SD) 770.4 (89.5) 732.5 (96.8) 690.9 (129.5) 
690.7 
(102.1) 
P=0.076 F=2.400 
2-back tR (SD) 809.2 (71.5) 788.5 (67.4) 727.6 (88.8) 730 (107.3) P=0.012 F=3.946 
 
Using the least-significant difference (LSD) post-hoc correction we found significantly longer reaction times 
only in the FEP group compared to the HC and to the ARMS-LT. 
Abbreviations: ARMS-ST – short-term ARMS; ARMS-LT – long-term ARMS; FEP - ‘first-episode 
psychosis’, HC - healthy controls; n-back errors – number of errors during n-back task, tR  - reaction time 
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Supplementary table 2: Group differences in gray matter volume 
Group 
comparisons 
pFWE-corr clustel 
level Voxels MNI x y z 
T at voxel 
level Side Brain region 
FEP<HC 0.0001 6817 
-10 -87 -5 
4 -66 7 
-20 -91 -3 
5.13 L, R Lingual gyrus and PCG (BA 17, 30) 
 0.0001 2349 
38 50 -20 
38 40 -21 
28 44 -15 
4.14 R MFG and SFG (BA 11) 
 0.0001 3414 
0 42 -2 
3 32 -2 
3 16 -11 
3.89 L, R ACG (BA 32, 24, 25) 
 0.001 1609 
27 -48 -14 
32 -34 -9 
40 -61 -17 
3.75 R Fusiform G and hippocampus (BA 37) 
 0.0001 4520 
-40 -49 -29 
-22 -42 -18 
-33 -64 -63 
 L Anterior lobe, culmen 
 0.0001 2168 
52 -12 40 
40 -6 64 
60 -7 33 
3.68 R PrecentralG and MFG (BA 4, 6) 
 0.0001 2407 -39 51 -20 -44 41 12 3.49 L 
MFG and IFG (BA11, 
46) 
 0.004 1309 45 -66 -57 3.18 R Cerebellum 
FEP<ARMS-LT 0.005 1296 
-56 -45 27 
-44 -46 25 
-45 -33 22 
4.05 L IPL extending into STG and insula (BA 40, 13) 
 0.0001 3203 
60 -4 -8 
32 -28 21 
48 -21 6 
3.78 R 
MTG extending into 
insula and STG (BA 21, 
13) 
 0.001 1589 
-24 -39 -39 
-38 -49 -29 
-22 -36 -24 
3.50 L Cerebellum, culmen 
FEP<ARMS-ST 0.002 1487 
50 15 1 
44 16 15 
51 15 30 
4.89 R IFG and MFG (BA 47, 44, 9) 
 0.002 1485 
-38 27 9 
-42 15 -3 
-54 15 -5 
4.35 L IFG (BA 45, 47, 22) 
 0.011 1137 
57 -33 37 
60 -42 49 
60 -27 33 
3.62 R IPL (BA 40) 
 0.025 984 
-38 -88 -21 
-28 -94 -21 
-48 -79 -17 
3.45 L IOG, Fusiform G, MOG (BA 18, 19) 
ARMS-ST<HC 0.010 1157 
16 40 -6 
3 24 -18 
-9 26 -12 
3.52 R, L Paracingulate G, ACG (BA 32, 25, 11) 
 0.017 1055 
-34 45 24 
-44 44 12 
-27 29 29 
3.44 L MFG extending into IFG (BA 10, 9, 46) 
ARMS-LT<HC 0.001 1567 
-6 33 21 
-2 44 -2 
-2 36 -12 
4.66 L ACG, paracingulate G (BA 24, 32, 11) 
 0.027 966 60 -7 22 45 -7 25 3.63 R 
Precentral gyrus (BA 4, 
6) 
ARMS-LT>HC 0.033 930 33 -28 22 33 -28 9 3.46 R 
Insula and transverse TG 
(BA 41) 
ARMS-
ST<ARMS-LT 0.018 1039 
58 -4 -8 
42 -19 6 
56 -16 0 
3.38 R 
MTG extending into 
insula and STG (BA 21, 
13, 22) 
 
There were no significant differences in contrasts: FEP>HC, ARMS-ST>HC, ARMS-ST>ARMS-LT, FEP>ARMS-
ST, FEP>ARMS-LT. 
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Supplementary table 2 abbreviations: 
ACG - anterior cingulate gyrus; ARMS-ST – short-term at risk mental state; ARMS-LT – long-term ARMS; BA - 
Brodman area; FEP – firt episode of psychosis; G - gyrus; HC - healthy controls; IFG - inferior frontal gyrus; IOG - 
inferior occipital gyrus; IPL - inferior parietal lobule; MFG - middle frontal gyrus; MOG - middle occipital gyrus, 
MOL - middle occipital lobe; MTG - middle temporal gyrus; PCG - posterior cingulate gyrus; SFG - superior 
frontal gyrus; TG – temporal gyrus. 
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Gray matter volumes (VBM results) 
The FEP group showed reduced GMV in the anterior cingulo-prefrontal, hippocampal, and occipito-
cerebellar regions, compared to HC group (P<0.01). Compared to the ARMS-LT, the FEP group had 
temporo-insular volumetric reductions (P<0.005). Compared to the ARMS-ST group, FEP had reduced 
volumes in the fronto-parietal and occipital regions (P<0.05). Both the ARMS-ST and ARMS-LT groups 
had anterior cingular and frontal volumetric reductions compared to the HC group (P<0.05). There was 
more GMV in insula in the ARMS-LT group compared to the HC group.  The ARMS-ST showed 
volumetric reductions in the temporal gyrus extending into insula, compared to the ARMS-LT group 
(Supplementary table 2).  
 
N-back fMRI results 
Main effect of task  
The main effect of task (2-back>0-back) in all 74 subjects delineates the network of activated areas 
independent of group. We used this task effect as a mask to constrain subsequent group analyses to a 
working memory network (Supplementary figure). 
 
 
Supplementary Figure: The main effect of 2-back>0-back brain activation across all 74 included subjects (FEP, 
ARMS-ST, ARMS-LT, and HC). 
The regional brain activation (P<0.001) was found in a network of areas that included the left middle and superior 
frontal gyrus (subsidiary focus of activation x=-32 y=0 z=54 and -2 6 60, voxels=23339), the bilateral superior and 
inferior parietal lobule (peak area of activation -10 -66 56, voxels=10128 and subsidiary focus of activation -56 -44 
22), the bilateral middle temporal gyrus (peak area of activation -30 -58 30, voxels=54 and subsidiary focus of 
activation 56 -54 -12), the right thalamus (10 -22 16), the left lentiform nucleus and putamen (-30 -20 -6), and the 
bilateral cerebellum (peak area of activation 32 -60 -30, voxels=202).  The left side of the brain is shown on the left 
side of the images, the axial, coronal and sagittal views are labelled with A, B and C respectively.  
  
A B C 
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Integrative image analysis using functional and structural imaging modalities 
Vulnerability-associated abnormalities of developing psychosis 
The ARMS-ST group activated less than the HC group in the bilateral superior and right inferior parietal 
lobule (P<0.0001), and in the left superior frontal gyrus (P<0.05; Table 2, Figure 1). The ARMS-LT 
group showed no significant functional differences compared to the HC group. 
 
 
 
Figure 1: Vulnerability-associated group differences in activation. 
The crosses show the peak area of different activation between the ARMS-ST and the HC groups. Clusters in the 
bilateral superior parietal lobule (x=-8; y=-64; z=48; voxels=2738, panel A), in the left superior frontal gyrus (-12 0 
62; voxels=312, panel B), and in the right inferior and superior parietal lobule (48 -44 52; voxels=741, panel C) reflect 
decreased regional brain activation in the ARMS-ST as compared to the HC group during the 2-back>0-back task 
(P<0.05). Covarying for GMV had no effect on these results. The left side of the brain is shown on the left side of the 
images. 
 
 
 
 
Figure 2: Psychosis-associated group differences in activation. 
The crosses show the peak area of different activation between the FEP and the ARMS-LT groups. Clusters in the left 
inferior and orbital frontal gyrus and insula (x=-32; y=34; z=0; voxels=1568, panel A), in the left superior frontal gyrus 
(-14 0 60; voxels=402, panel B), and in the left inferior and middle frontal gyrus (-34 26 18; voxels=689, panel C) reflect 
decreased regional brain activation in the FEP as compared to the ARMS-LT group during the 2-back>0-back task 
(P<0.01). After covarying for GMV the cluster in the right inferior frontal gyrus and insula (26 22 2; voxels=406, panel 
D) became significant. The left side of the brain is shown on the left side of the images.  
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Psychosis-associated abnormalities 
The FEP group showed less brain activation in the bilateral precuneus extending into superior parietal 
lobule and in the left superior and middle frontal gyrus (P<0.0001) compared to the HC group. Compared 
to the ARMS-LT, the FEP group showed reduced activation in the bilateral inferior frontal gyrus and 
insula, in the left superior frontal gyrus, and in the middle frontal gyrus (P<0.01; Table 2, Figure 2). 
Correlation analyses in the FEP individuals under BPM confirmed a negative interaction between BOLD 
response and GMV in right precuneus (36 -72 44; P=0.032). There were no significant differences in 
brain activation in the FEP group compared to the ARMS-ST group. 
 
Neurofunctional abnormalities associated with high probability to develop psychosis 
Compared to the ARMS-LT, the ARMS-ST subjects showed reduced activation in the right inferior 
frontal gyrus extending into insula (p<0.05) and in the left superior frontal gyrus, insula and bilateral 
precuneus (p<0.1) (Figure 3, Table 2). There was a positive correlation between BOLD response and 
GMV in left precuneus (-28 -72 24; P=0.003) in the ARMS-ST group; and in right insula (42 -18 -10; 
P=0.015), left inferior frontal gyrus (-32 32 -18; P=0.002), and in right lingual gyrus (32 -72 -12; 
P=0.0001) in ARMS-LT group.  
 
 
 
Figure 3: Group differences in brain activation between the ARMS-ST and the ARMS-LT groups.  
The clusters reflect decreased regional brain activation in the right inferior frontal gyrus and insula (x=42; y=18; z=-4; 
voxels=303; P<0.05, panel A) and in bilateral precuneus (18 -78 48, voxels= 243, P<0.1, panel B) in ARMS-ST as compared to 
ARMS-LT group during the 2-back>0-back task. Covarying for GMV caused loss of significance in left superior frontal gyrus (-
10 -4 66, voxels= 229, panel C), and in left insula (-38 14 0, voxels= 224, P<0.01, panel D). The left side of the brain is shown 
on the left side of the images.  
 
Effects of antipsychotic medication on neurofunctional activation 
The analyses were repeated after exclusion of all subjects on antipsychotic medication. With exception of 
one cluster in the right middle frontal gyrus that lost its significance, the same set of regions showed 
significant differences between the FEP and HC groups. The differences in brain activation between FEP 
and ARMS-LT groups remained unchanged with one new significant cluster appearing in the left 
subthalamic and lentiform nuclei (-10 -14 -6). The results of repeated analyses in ARMS-ST and ARMS-
LT groups showed no differences in brain activations (Table 2).  
  
A B D C 
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Table 2: Group differences in brain activation. 
Group comparisons pFWE-corr clustel level Voxels MNI x y z 
T at voxel 
level Side Brain region  
FEP < HC 0.0001 3586 
2 -56 46 
-18 -56 62 
-6 -62 52 
4.92 R, L PCu extending into SPL and cuneus (BA 7) 
  0.0001 949 
-12 2 62 
-34 2 54 
-20 14 52 
4.62 L SFG and MFG (BA 6) 
  0.109 (0.024) 207 
26 20 48 
36 14 50 
24 18 56 
3.25 R MFG and SFG (BA 6, 8)*+ 
FEP < ARMS-LT 0.0001 1568 
-32 34 0 
-26 22 -4 
-26 28 4 
4.54 L IFG, insula and OFG (BA 47,13)+ 
  0.006 402 
-14 0 60 
-18 -2 72 
-10 16 64 
3.97 L SFG (BA 6) 
  0.0001 689 
-34 26 18 
-36 50 14 
-48 16 46 
3.55 L IFG and MFG (BA 13, 10, 8)+ 
  0.006 (n.s.) 406 
26 22 2 
30 34 -2 
34 24 14 
3.82 R IFG extending into insula (BA 47)* 
ARMS-ST < HC 0.0001 2738 
-8 -64 48 
4 -56 46 
-22 -78 40 
4.82 L, R SPL, Pcu (BA 7) 
  0.022 312 -12 0 62 -14 10 52 3.81 L SFG (BA 6, 32) 
  0.0001 741 
48 -44 52 
52 -44 44 
36 -64 60 
3.20 R IPL and SPL (BA 40, 7) 
ARMS-ST < ARMS-
LT 
0.025 
(0.056) 303 
42 18 -4 
34 34 -2 
26 22 -2 
3.69 R Insula and IFG (BA 47, 13)* 
  0.077 (0.023) 229 
-10 -4 66 
-18 -4 70 3.52 L SFG (BA 6)*+ 
 0.083 (0.039) 224 
-38 14 0 
-26 20 -4 
-28 20 6 
3.51 L Insula (BA 13, 47)* 
 0.062 243 
18 -78 48 
28 -82 36 
-2 -74 54 
3.50 R, L Pcu (BA 9, 17) 
 
Brain activation differences calculated using ANCOVA analyses in BPM of 2-back>0-back contrast with two non-
imaging covariates (gender, age) and one imaging covariate VBM-GM. 
*Cluster changed its significance after covarying for GMV (P value without VBM–GMV imaging covariate in 
parentheses)  
+Cluster lost its significance after exclusion of medicated individuals (8 FEP, 2 ARMS-LT)   
There were no significant differences in contrasts: FEP>HC, ARMS-ST>HC, ARMS-LT<HC, ARMS-LT>HC, 
ARMS-ST>ARMS-LT, FEP<ARMS-ST, FEP>ARMS-ST, FEP>ARMS-LT. 
Two clusters (with symbol+) lost its significance after exclusion of 10 medicated patients from our FEP<ARMS-LT 
analysis. There was one big subcortical cluster that became significant encompassing the left subthalamic and 
lentiform nucleus (MNI x,y,z: -10 -14 -6; 1143 voxels; P=0.0001, FWE corrected) and two smaller ones in the right 
middle and the superior frontal gyrus (42 -46 2; 324 voxels; P=0.017, FWE corrected) and in the left inferior 
parietal lobule (-32 -44 50; 299 voxels; P=0.024, FWE corrected). 
 
Abbreviations: ARMS-ST – short-term ARMS; ARMS-LT – long-term ARMS ; BA - Brodman area, FEP - ‘first-
episode psychosis’, FG - frontal gyrus, HC - healthy controls; IFG - inferior frontal gyrus; IPL - inferior parietal 
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lobule; MFG - middle frontal gyrus; Pcu - Precuneus; n.s. – non significant, OFG – orbital frontal gyrus; SFG - 
superior frontal gyrus; SPL - superior parietal lobule 
DISCUSSION 
With a multimodal image analysis we investigated individuals at high-risk of psychosis and patients with 
the established illness. We used BPM toolbox in order to differentiate between vulnerability-associated 
and psychosis-associated abnormalities in the neural substrate of working memory function in 
conjunction with volumetric data. Comparing ARMS-ST and HC revealed that vulnerability to psychosis 
was associated with a reduced activation in the bilateral superior and inferior parietal lobules as well as in 
the left superior frontal gyrus. Compared to ARMS-LT individuals, those with the ARMS-ST showed 
reduced activation in the right insula and inferior frontal gyrus. Comparing the FEP patients to the 
ARMS-LT subjects revealed that full-blown psychosis was associated with reduced activation in the 
bilateral inferior frontal gyrus extending into insula, and in left superior, inferior and middle frontal gyri.  
We recorded the time from the first presentation of subjects with ARMS and divided them into two 
subgroups comparable with the new staging model for psychosis (McGorry et al., 2009). The mean 
duration of the ARMS was 4.5 years in the ARMS-LT group; thus the probability that any of these 
subjects would develop psychosis in the future was rather low (Cannon et al., 2008; Riecher-Rössler et 
al., 2009). In the ARMS-ST subjects, we expect a transition rate of approximately 30% (Mechelli, 2010; 
Riecher-Rössler et al., 2009) in the next one–two years. Splitting the ARMS subjects into two groups 
allows a better understanding of a real subsequent probability to develop psychosis. This may help to 
investigate psychosis-associated functional abnormalities in the FEP (individuals with psychosis itself) in 
contrast to the ARMS-LT (individuals with vulnerability but very low transition probability to psychosis). 
This particular comparison removes any psychosis specific effects (inherent in the 30% of ARMS who 
might transit) making the ARMS-LT versus FEP comparison a ‘purer’ contrast to psychosis. The ARMS-
ST group with 30% probability to develop psychosis subsequently was a basis to investigate vulnerability 
connected with higher transition probability-associated changes in brain activation compared to the HC. 
Interestingly, our ARMS-LT did not differ from the ARMS-ST with respect to age, even included longer 
time ago in ARMS. This could be because of small sample sizes and needs further investigation. On the 
other hand, the difference between ARMS-ST and ARMS-LT are not attributable to the effect of aging in 
one of those groups. We can speculate that the differences between these two groups in the n-back 
activation network showed not only disrupted function in the ARMS-ST group, but resilience or 
protective processes in the ARMS-LT group. 
The present study was powered to detect group effects on activation rather than on task performance. 
However, the two ARMS groups showed differences in reaction times during the most demanding 
condition. The FEP and ARMS-ST groups needed longer during 2-back condition compared to the HC 
and the ARMS-LT groups. According to the previously published studies (Delawalla et al., 2008; Sanz et 
al., 2009) the FEP and ARMS-ST groups might be lower performing and show prefrontal hypo-
activation. There is evidence indicating that working memory functioning in prodromal psychosis is 
related to striatal dopaminergic alterations in a non-linear (i.e. U curve) fashion (Fusar-Poli et al., 2010b). 
However, it may be because all group contrasts were based on 2-back > 0-back condition, it means when 
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the task gets harder. Thus, the compensation model might predict hypo-activation (Callicott et al., 2003b) 
due to a ceiling effect of going downwards on the inverted U-shaped curve. Individuals with more 
psychotic symptoms (FEP, ARMS-ST) thus could reach the peak of the inverted U-curve sooner than less 
symptomatic (ARMS-LT and HC) individuals.  Apart from that the behavioral differences may be due to 
attentional impairments seen in schizophrenia patients (Karch et al., 2009), the symptom severity, and 
medication. Previous studies report impaired working memory performance in the ARMS (Eastvold et al., 
2007; Pflueger et al., 2007), although other studies find no effect on task performance in the ARMS 
(Broome et al., 2010; Broome et al., 2009; Fusar-Poli et al., 2010a; Fusar-Poli et al., 2010b) or in the FEP 
(Ettinger et al., 2011). However, functional neuroimaging techniques are able to detect physiological 
changes, and are likely to be more sensitive than behavioural measures (Wilkinson and Halligan, 2004). 
Furthermore, the image analyses were restricted to correct responses and the observed differential 
activations reflect differences at the neurophysiological level and not on task performance. 
Overall, we found working memory-associated activations in the prefrontal and parietal cortex in all our 
subjects during WM task, corresponding to previously published data of patients with an ARMS (Broome 
et al., 2009; Fusar-Poli et al., 2010a) and psychosis (Callicott et al., 2003a; Callicott et al., 2003b; Forbes 
et al., 2009). Vulnerability-associated functional abnormalities in the superior frontal gyrus and in parietal 
lobules distinguished the ARMS-ST from HC group and corresponded to the previous fMRI studies with 
altered prefrontal brain activation (Fusar-Poli et al., 2009; Fusar-Poli et al., 2010b) for review see 
reference (Fusar-Poli et al., 2007a). Compared to the HC, both the ARMS-ST and ARMS-LT groups 
showed reduced GMV in the anterior cingulate, middle and inferior frontal gyri. These findings are 
similar to the published volumetric abnormalities found in ARMS (Borgwardt et al., 2008; Borgwardt et 
al., 2007b; Fornito et al., 2008; Koutsouleris et al., 2009; Meisenzahl et al., 2008; Pantelis et al., 2003; 
Sun et al., 2009) and to those found at meta-analytical voxel-based level (Fusar-Poli et al., 2011). 
Interestingly, we found probably compensatory more GMV in insula in the ARMS-LT compared to the 
HC group. 
The neurofunctional reduction in the ARMS-ST versus ARMS-LT group revealed the difference between 
the higher and lower transition probability. Only one cluster in the right inferior frontal gyrus and insula 
distinguished these two groups after covarying for gray matter volume using BPM. Furthermore, reduced 
activation in the left inferior frontal gyrus, the right insula, and in the bilateral precuneus positively 
correlated with volumetric deficits in these regions within the ARMS-LT and ARMS-ST individuals, 
respectively. A previous study by Fusar-Poli et al. (Fusar-Poli et al., 2010a) showed that the prefrontal 
functional abnormalities in ARMS are related to GMV. Our results are comparable to the prefrontal 
abnormalities found in ARMS (Fusar-Poli et al., 2010a) and to the altered function found in precuneus in 
unaffected siblings of schizophrenia patients (Liu et al., 2010). Furthermore, reduced GMV in the right 
temporal gyrus and insula delineate the difference between the ARMS-ST and the ARMS-LT group. 
These are the regions known to be different in ARMS with and without subsequent transition to psychosis 
(Borgwardt et al., 2007b). 
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Comparing the FEP with ARMS-LT individuals, we observed functional differences in the bilateral 
inferior frontal gyrus and insula, and in left superior and middle frontal gyrus, that may delineate 
psychosis-associated changes. These functional alterations during the WM task resemble those reported 
previously in schizophrenia patients in prefrontal (Barch et al., 2001; Cannon et al., 2005; Johnson et al., 
2006; Manoach et al., 2000; Manoach et al., 1999; Menon et al., 2001; Perlstein et al., 2001; Tan et al., 
2005), and temporal (Fusar-Poli et al., 2007a; Glahn et al., 2005; Karch et al., 2009; Schneider et al., 
2007) regions. 
In agreement with our hypothesis, the ARMS-LT and the ARMS-ST groups showed more WM-related 
activation than the FEP and less than the HC group. We found neither neurofunctional nor behavioral 
differences between FEP and ARMS-ST group. Taking into account 20-30 % transition probability to the 
psychosis, the major part of this group will subsequently belong to the ARMS-LT group, physiologically 
different from the FEP group. We can deduce that the ARSM-LT group has not only lower transition 
probability (Riecher-Rössler et al., 2009) but as well some resilience factors, which helped those 
individuals to avoid the imminent psychosis.  
The ARMS is understood as a dynamic process (Simon and Umbricht, 2010; Yung et al., 2010) 
concerning structural and functional brain abnormalities (Fusar-Poli et al., 2007a), disrupted cellular 
integrity and connectivity (Green, 2007), and other still unknown factors. We showed that 
neurofunctional abnormalities are associated with structural deficits in the ARMS-ST and ARMS-LT 
groups, as they changed its significance in insular and inferior and superior frontal regions after covarying 
for GMV. Using a well-established working memory paradigm, we found functional vulnerability-
associated abnormalities in a fronto-parietal network, whereas abnormalities associated with psychosis 
itself in frontal and insular brain activations. We presume that dynamic processes in task-relevant regions 
underline positive functional-structural correlation in the early stages of ARMS (ARMS-ST, ARMS-LT) 
and the negative correlation in the FEP group. It remains unknown, whether functional abnormalities 
precede the structural ones, how reversible they are, and if they are compensatory in their nature. In 
future, a multimodal approach combining fMRI and sMRI results with connectivity measurements or 
combining optical and genetic techniques(Lee et al., 2010b) could help to improve understanding of 
neural circuits underlying psychosis and ARMS. 
The neurofunctional abnormalities we observed could not directly be attributed to antipsychotic 
treatment, as all of the ARMS-ST were antipsychotic-naïve and only 12% of the ARMS-LT had 
antipsychotic treatment at the time of scanning. Although the exclusion of 38% antipsychotic-medicated 
FEP patients did not substantially change our results, we probably found a protective effect of 
antipsychotics in the subcortical structures. For all other comparisons after excluding medicated 
individuals from analyses the results remained largely unchanged. The influence of antipsychotics on the 
brain function is not entirely clear, however antipsychotics may affect neural activity (Lui et al., 2010) 
and GMV (Tost et al., 2010), especially in basal ganglia (Smieskova et al., 2009). Furthermore, all of 
those on antipsychotics were treated with atypical compounds in very low doses.  
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Some limitations of this study should be considered. Firstly, although one subject of the ARMS-ST group 
developed psychosis during the follow-up, the small sample size did not allow meaningful analyses 
regarding the clinical outcome. Secondly, our specific FEP population included mostly outpatients at the 
beginning of their disease with relatively high premorbid IQ values compared to chronically ill psychotic 
patients at a later stage of the illness (Urfer-Parnas et al., 2010). Thirdly, although the FEP group had less 
formal education than the other groups, this could not account for the differences between the ARMS-ST 
and ARMS-LT and control groups, which were matched regarding these aspects. Fourthly, although the 
ARMS-ST group has a higher probability of transition to psychosis, thus there is a non-transition 
probability of approximately 70%. The neurofunctional differences found in this group could be even 
more pronounced in the pure transition subgroup. Fifthly, we have not examined the association with an 
affective psychosis, borderline personality disorder or other comorbidities with the ARMS. Assessment 
of other psychopathological measures could lead to better distinction characteristics of ARMS-ST and 
ARMS-LT group. However, this was not the main aim of the study. Sixthly, we have not studied the 
default mode network independent of the WM-task and cannot thus exclude the anomalous network 
connectivity (Whitfield-Gabrieli et al., 2009) in included individuals. Such functional connectivity 
analysis could extend the understanding of ARMS-underlying processes. Finally, the pure transition 
group could show more pronounced differences, but the differences seen even at the very early beginning 
of the ARMS in ARMS-ST, showed us the regions playing the crucial role in the dynamic ARMS 
process.  
 
CONCLUSION 
In this study we found distinct patterns of mnemonic neurofunctional brain activation related to 
vulnerability to psychosis as opposed to psychosis itself. Neurofunctional alterations in fronto-parietal 
regions may be correlates of vulnerability to psychosis whereas more pronounced neurofunctional 
abnormalities in prefrontal cortex were associated with the presence of psychosis. Our results thus 
confirm the hypothesis of a disrupted working memory network during the development of psychosis. 
Additionally, neurofunctional differences within the ARMS were related to different duration of ARMS. 
These abnormalities were directly related to volumetric reduction. 
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Chapter 5 
 
SUMMARY AND DISCUSSION 
 
A task to improve the understanding of the psychosis, its cause, course and prevention is extremely 
complex. Studying populations suffering from schizophrenia means to take into account many 
confounding factors that make the investigation even more complex. Based on the known effect of 
antipsychotics on brain volume (Dazzan, et al. 2005; Konopaske, et al. 2008), we wanted to uncover the 
differences between psychotic individuals medicated with different types of antipsychotics. 
Secondly, we aimed at characterizing the vulnerability markers of psychosis in individuals who are at 
high risk to develop psychosis and have minimum of confounders influencing the results. We did so in 
our meta-analysis of existing studies, comparing individuals prone to transition to psychosis according to 
their subsequent outcome – with or without later transition to psychosis. 
Thirdly, we wanted to improve understanding of vulnerability- and psychosis-associated abnormalities in 
population of antipsychotic-naive subjects. We introduced a new concept of splitting ARMS population 
according to the duration of the risk-state and their probability to transit to psychosis. The criterion to 
split ARMS according to the duration of their risk-state was assigned at two years after ascertainment and 
was based on differences in transition probability. In our two groups with different transition probabilities 
we compared their gray matter volumes and investigated working memory-related neurofunctional 
differences in brain activation. 
In chapter 4.1, twenty-four longitudinal and six cross-sectional studies of schizophrenic patients with 
antipsychotic medication were reviewed. We investigated the effect of antipsychotics on the brain 
structure in schizophrenia and found reduced gray matter volume particularly in the frontal and temporal 
lobes. Structural neuroimaging studies indicate that treatment with typical as well as atypical 
antipsychotics may affect regional gray matter volume. Studies with typical antipsychotics reported 
increased gray matter in the cingulate cortex, in contrast to the atypical antipsychotics with the excess 
more often seen in the thalamus. Our conclusions of antipsychotic-related alterations of brain structure in 
schizophrenia have been recently confirmed by a long-term follow-up study in 211 patients (Ho, et al. 
2011b). 
Neuroimaging predictors of later transition to psychosis were analyzed in chapter 4.2. The meta-analysis 
showed that total brain volume and total gray matter volume were increased in individuals who made 
transition to psychosis compared to the individuals without transition, but as well as to the first episode of 
psychosis individuals. At the other side we found reduced regional gray matter volume in insula, anterior 
cingulate, prefrontal cortex, and cerebellum. Thus, vulnerability markers to psychosis seem to be subtle 
and region-specific. The counter-intuitive increased global brain volume in the group of ARMS who 
made transition could reflect efforts of the brain to compensate for regional abnormalities. This 
compensatory increment could involve various cellular processes not only in neurons, but as well as in 
the neuropil. A recent longitudinal study of first-episode patients with minimal antipsychotic treatment 
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before study enrolment showed that less illness severity was associated with increased brain tissue 
volumes (Ho, et al. 2011b). This result correspond to our finding of increased total brain volume and total 
gray matter volume in the ARMS-T individuals with less sever symptoms as compared to the first 
episode patients. 
Meta-analysis of functional studies showed reduced activation in regions where we found regional 
volumetric deficits: prefrontal and cingulate cortex and in occipital lobe. Those structural and functional 
results are not confounded by medication and could be seen as neuroimaging predictors of transition to 
psychosis. 
Chapter 4.3 showed structural differences in ARMS individuals with different transition probabilities to 
psychosis and putative resilience factors. Compared to the ARMS-LT, the ARMS-ST group expressed 
significant reductions in grey matter volume in prefrontal, insular and middle temporal areas, consistently 
implicated in volumetric neuroimaging studies of high-risk individuals for schizophrenia (Borgwardt, et 
al. 2007a; Borgwardt, et al. 2008; Borgwardt, et al. 2007b; Koutsouleris, et al. 2009; Pantelis, et al. 
2003a; Takahashi, et al. 2009a; Takahashi, et al. 2009b). Comparing the ARMS-ST to the ARMS-LT 
subjects showed increase of the right insular volume. Interestingly, this gray matter volume (GMV) 
increase was detectable also in the ARMS-LT compared to the HC group. Therefore, the increase of the 
right insular volume could be associated with the resilience factors. Contrary to that, the reduced right 
insular volume was associated with higher transition probability. Negative symptoms correlated 
negatively and global functioning positively with volumetric differences between ARMS. 
Working memory related brain activation was a basis to investigate neurofunctional differences between 
individuals at high-risk of psychosis and patients with the established illness. In chapter 4.4 we showed 
that neurofunctional abnormalities were associated with structural deficits in the ARMS-ST and ARMS-
LT groups. The neurofunctional abnormalities changed their significance in insular and frontal regions 
after covarying for GMV. Using a working memory paradigm, we found functional vulnerability-
associated abnormalities in a fronto-parietal network, whereas abnormalities associated with psychosis 
itself in frontal and insular brain activations.  
Vulnerability-associated altered prefrontal brain activation corresponded to the previous fMRI review 
(Fusar-Poli, et al. 2007a). Reduced activation in the inferior frontal, insular, and precuneus regions 
positively correlated with volumetric deficits in these regions within the ARMS-LT and ARMS-ST 
individuals, corresponding to the previous studies (Fusar-Poli, et al. 2010c; Liu, et al. 2010). Psychosis-
associated functional alterations in frontal gyri and insula during the WM task resemble those reported 
previously in schizophrenia patients in prefrontal (Barch, et al. 2001; Cannon, et al. 2005; Johnson, et al. 
2006; Manoach, et al. 2000; Manoach, et al. 1999; Menon, et al. 2001; Perlstein, et al. 2001; Tan, et al. 
2005), and temporal regions (Fusar-Poli, et al. 2007a; Glahn, et al. 2005; Karch, et al. 2009; Schneider, et 
al. 2007).  
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Limitations 
 
Several limitations of our studies must be acknowledged. First of all, using neuroimaging methods does 
not enable us to detect direct pathophysiological differences such as neuronal or glial loss or 
abnormalities at the receptor level. The differences we have detected are delimitated by white or gray 
matter volume and by difference in oxygenated and deoxygenated blood in the VBM and in the fMRI 
study, respectively. It is extremely important to formulate the MRI results and implications very carefully 
and truthfully. 
Secondly, fMRI, that allows in vivo investigation of the human brain in terms of various blood flows in 
different brain regions, is not able to identify the neural networks underlying specific condition. The 
existence of different imaging packages (e.g. SPM – parametric and XBAMM – non-parametric analysis) 
contributes to the heterogeneity of findings (Fusar-Poli, et al. 2010a).  
Thirdly, although VBM allows comparison of the whole brain at the single voxel level, there are still 
relevant problems connected to the brain registration (Ashburner and Friston 2000), smoothing kernel and 
labeling of results according to the human brain atlases and probabilistic brain maps. Furthermore, exact 
meaning of the volumetric abnormalities could reflect various neuropathological changes, e.g. impaired 
structure of neurons and glial cells, or neurotoxic effect of various substances. Furthermore, different 
scanning parameters and analytical approaches contribute to the inconsistencies in MRI measures. 
Fourthly, our analyses are based on the between-group comparison and thus do not allow any prediction 
for individual patients. It is necessary to reproduce our and others’ results and to provide bigger 
multicenter studies aiming on characterizing vulnerability markers for transition to psychosis that could 
be used in a clinical praxis. The criterion to split ARMS according to the duration of their risk-state, 
assigned on the two years after ascertainment, helps to distinguish between vulnerability- and resilience-
associated factors. However, the relevance of this new approach needs to be confirmed in a longitudinal 
follow-up study that we are currently planning. 
Fifthly, assessment of other psychopathological measures (affective psychosis, borderline personality 
disorder or other comorbidities) could lead to better distinction characteristics of ARMS-ST and ARMS-
LT group. The subsequent analyses with bigger sample sizes and with orientation on diagnoses could help 
to investigate these aspects.  
Sixthly, although our studies included follow up of clinical outcome, MR scanning was done at baseline. 
However, when comparing different groups of subjects, it is difficult to control for effects related to other 
variable than the parameter of interest. This potential confound can be overcome in a longitudinal design. 
Re-scanning individuals after their transition to psychosis or after subsequent setting of other psychiatric 
diagnosis could improve the understanding of vulnerability and resilience factors.  
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Conclusions and implications 
 
Brain structural abnormalities in individuals treated with antipsychotics were clearly associated with an 
effect of antipsychotic medication. Both types of antipsychotic medication led to the changes in the brain 
structure in regional and global measures. This evidence indicates the importance of reasonable and well-
monitored use of antipsychotics, in particular in off-label conditions as high-risk individuals (Simon and 
Umbricht 2010; Ziermans, et al. 2010).  
We showed in our meta-analysis that individuals with later transition to psychosis (ARMS-T) compared 
to those without transition (ARMS-NT) had neuroanatomical and neurofunctional abnormalities in 
prefrontal, cingulate, temporal, and cerebellar cortex. They correspond to the neurocognitive 
abnormalities in high-risk individuals (Fusar-Poli, et al. 2007a). 
Majority of studies concentrate on the individuals with later transition to psychosis, ARMS-T. The larger 
proportion of ARMS individuals remains virtually neglected. Based on these facts, we argue that the 
ARMS-LT could help us to better understand compensatory or resilient processes in high-risk 
individuals.  Their potential psychiatric diagnoses could help us to understand comorbidities and similar 
characteristics with other symptoms.   
Structural deficits in ARMS were associated with the decline in functioning and with negative symptoms. 
Vulnerability-associated structural abnormalities were found in orbitofrontal network, whereas 
abnormalities associated with higher transition probability to psychosis in insular and middle temporal 
brain regions. Resilient volumetric changes could be detected in in the ARMS-LT group with lower 
probability for transition to psychosis.  
Mnemonic neurofunctional alterations in fronto-parietal regions may be correlates of vulnerability to 
psychosis whereas more pronounced abnormalities in prefrontal cortex are associated with the presence 
of psychosis. Additionally, neurofunctional differences within the ARMS were related to different 
duration of ARMS. These abnormalities were directly related to volumetric reduction. We used 
multimodal approach to investigate functional and structural imaging data in conjunction and tried to 
characterize neuroanatomical and neurofunctional correlates of liability to psychosis. In future, 
multivariate neuroimaging analyses (e.g. support vector machine (Koutsouleris, et al. 2010)) could help to 
predict the disease transition on an individual level. 
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Amsterdam, Netherlands, November 2010. 
• A meta-analysis of neuroimaging predictors of transition to psychosis. Poster presentation on the ECNP 
Workshop on Neuropsychopharmacology for Young Scientists in Europe Nice, France, March 2010. 
• The effects of antipsychotics on brain structure – a systematic review. Poster presentation on the annual 
conference of Swiss Society of biological Psychiatry (SSBP) and Swiss Society of Sleep Research, Sleep 
Medicine and Chronobiology (SSSC) in Bern, Switzerland, March 2009. 
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